



DR. M. I. QADIR

PhD (QAU), M Phil (QAU), B Pharm (BZU),
DHMS (Pb), DIMS (Pb), MAcF (Pak), MD (AM, Sri Lanka),
PgC (Chest & Heart), PgC (Research), PgC (Chem Path),
RPh (Pb), RHMP (Pak), MHOC (Pak).

**Assistant Professor, Institute of Molecular Biology and Biotechnology,
Bahauddin Zakariya University, Multan, Pakistan**

☎: +92-301-6515613

INVENTIONS & DISCOVERIES: INNOVATIONS IN REAL LIFE

1. Qadir Test:

A new cost-effective and convenient method for early diagnosis of cancer. Plasma lipid profile is changed in cancer patients. So, the change in plasma lipid profile may be used for diagnosis of cancer.

2. Qadirvirtide:

A synthetic peptide composed of 36 amino acids classified as HIV fusion inhibitor for management of AIDS.

3. Qadir-C34:

A synthetic peptide composed of 34 amino acids classified as HIV fusion inhibitor for management of AIDS.

4. Qadirphages:

Preparations containing locally isolated bacteriophages with antibacterial activity.

Qadirphage A (QφA): Isolated from *Escherichia coli*

Qadirphage B (QφB): Isolated from *Pseudomonas aeruginosa*

Qadirphage C (QφC): Isolated from *Streptococcus pneumonia*

5. Qadir's Theory of Cancer Etiology:

All cancers are caused by viruses, a theory published in highly impacted international journal. Therefore, cancer may be cured by eradication of viral infections.

6. Qadir's Pronunciation: An English alphabet should be pronounced exactly as it is pronounced in a word known as "Qadir's Pronunciation" of Alphabets. Similarly, Urdu Hija should also be pronounced exactly as it is pronounced in a word known as "Qadir's Pronunciation" of Urdu Hija.

7. Pharmacological Activities of Local Plants

Worked to evaluate the pharmacological activities of local plants and established use of many local plants for jaundice/hepatitis, hypertension, diabetes, spasm, ulcer, diarrhea, and infectious diseases of bacterial and fungal origin.

8. Isolation and Structure Elucidation of Bioactive Compounds

Also worked on the isolation and structure elucidation of bioactive substances from medicinal plants and has resulted in the discovery of several new/novel natural compounds, like Pentandraol, Pentandradione.

9. Solution of Drug Delivery Problems

The problem of resistance and tolerance to the existing drugs has created a decreased efficacy of these drugs in use. This problem has been tried to be overcome by increasing the drug delivery to the target site by the use of polymers or through nanotechnology.

10. Identification of Mechanisms

Identified different biological and pharmacological pathways which are important for diagnosis and management of different diseases.

GENERAL BIODATA

Name: Muhammad Imran Qadir
S/O: Muhammad Zulfiqar Ali
Gender: Male
Marital Status: Married, Two Children
Date of Birth: 03-09-1978
Nationality: Pakistani
NIC #: 36304-0585154-3
Domicile: Multan (Punjab)
Permanent Address: F-129, Buch Executive Villas, Bosan Road, Multan, Pakistan
Postal Address: Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan
Email: mrirranqadir@hotmail.com
Contact: +92-301-6515613 (Mobile)
+92-61-9210071 Ext. 1920 (Office)

QUALIFICATION

Matriculation (Science) 1994
1st Division (64.82 %), Govt. High School Shujabad, Multan Board

FSc (Pre-Medical) 1997
1st Division (74.64 %), Govt. Degree College Shujabad, Multan Board

B Pharmacy 2001
1st Division (62.11 %), Bahauddin Zakariya University, Multan
Major Subjects: Pharmacology, Pharmaceutics, Pharmaceutical Chemistry

M Phil (Biochemistry and Molecular Biology) 2005
Quaid-I-Azam University, Islamabad
Major Subjects: Molecular Biology, Genetic Engineering, Biochemistry
Research Title: “Alteration in plasma lipid profile as biochemical marker for diagnosis of neoplastic disease”

Ph D (Biochemistry and Molecular Biology) 2011
Quaid-I-Azam University, Islamabad
Research Title: “Genetic Variation in HR regions of *env* gene of HIV in Pakistan”

DIPLOMAS

Diploma in Acupuncture (MAcF)	2003
Open International University for Complementary Medicine, Colombo, Sri Lanka	
Diploma in Islamic Medical Science (DIMS)	2005
National College Farogh-e-Hikmat, Lahore, Pakistan	
Diploma in Homeopathic Medical Science (DHMS)	2008
Rawal Homeopathic Medical College and Hospital, Rawalpindi, Pakistan	
MD (Alternative Medicine)	2010
Open International University for Complementary Medicine, Colombo, Sri Lanka	
<i>Research Title:</i> “Effectiveness of laser therapy in male sexology”	

EXPERIENCE

M. S. Enterprises Ltd. (Pharmaceutical Division), Lahore

Production Pharmacist 10th October 2001 – 31st October 2002

Responsibilities: Production of IV infusions.

Riphah International University, Islamabad

Lecturer 1st November 2002 – 31st March 2006

Responsibilities: Teaching Biochemistry to Graduate Students.

University of Lahore (Islamabad Campus), Islamabad

Assistant Professor 1st April 2006 – 30th June 2008

Responsibilities: Teaching Biochemistry to Graduate Students.

The University of Faisalabad, Faisalabad

Assistant Professor 1st July 2008 – 20th September 2008

Responsibilities: Teaching Biochemistry to Graduate Students.

College of Pharmacy, GC University, Faisalabad

Assistant Professor 22nd September 2008 – 3rd September 2014

Responsibilities: Teaching Biochemistry and research for M Phil students.

Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan

Assistant Professor 9th September 2014 – Continued

Responsibilities: Teaching to BS, MSc and research for M Phil students.

ADMINISTRATIVE/VISITING EXPERIENCE

Administrative/visiting teaching/research experience and academic consultancy as:

1. **Head, Department of Pharmaceutical Chemistry,**

Faculty of Pharmacy, GC University, Faisalabad (From 16-04-2014 to 03-09-2014)

2. **Incharge, College of Pharmacy,**

GC University, Faisalabad (From 02-08-2012 to 22-10-2012)

3. **Member, Board of Studies,**

College of Pharmacy, GC University, Faisalabad (2013)

4. **Member, PhD Synopsis Review Committee,**

Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan (From 28-08-2017 to date)

5. **Member, Committee for Dengue Control,**

GC University, Faisalabad (From 29-08-2012 to 03-09-2104)

6. **Member, Synopsis Review Committee,**

GC University, Faisalabad (From 02-08-2012 to 03-09-2104)

7. **Secretary, Budget Advisory Committee,**

College of Pharmacy, GC University, Faisalabad (From 23-02-2009 to 22-10-2012).

8. **Visiting Lecturer (Biochemistry),**

Department of Pharmacy, University of Faisalabad, Faisalabad (2009).

9. **Visiting Lecturer (BHMS),**

Rawalpindi Homeopathic Medical College, Rawalpindi (2005).

10. **Research Fellow,**

Army Medical College, Rawalpindi (From 01-04-2004 to 28-02-2005).

11. **Marketing Executive,**

Institute of Health Management, Islamabad (2004).

12. **Visiting Lecturer (Parenteral Preparations),**

Lahore College of Pharmaceutical Sciences, Lahore (From Feb 2002 to Jun 2002).

TEACHING ACTIVITIES

Courses Taught:

Under-graduate Level (Pharm D/BHMS/BS/MSc): Parenteral Preparations, Pathology, Biochemistry, Pharmacognosy, Pharmacology, Pharmaceutical Chemistry (Organic), Pharmaceutical Chemistry (Medicinal), Cell Biology, Organic Chemistry, Statistics, Inorganic Chemistry, Bioinformatics, Immunology, Animal Biotechnology, Food Biotechnology, Pharmaceutical Biotechnology, Health Biotechnology

Post-graduate Level (M Phil/PhD): Human Molecular Genetics, Medical & Animal Biotechnology, Advances in Microbiology, Advances in Immunology, Battery of Pharmacology, Analytical Pharmacognosy, Research Methods in Biotechnology

External Examiner for other Institutions:

1. Department of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan
2. Department of Pharmacy, GC University, Faisalabad, Pakistan
3. Department of Pharmacy, University of Faisalabad, Faisalabad, Pakistan
4. Department of Chemistry, University of Agriculture, Faisalabad, Pakistan
5. Department of Pharmacy, University of Agriculture, Faisalabad, Pakistan
6. Department of Pharmacy, University of Malakand, Malakand, KPK, Pakistan
7. Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, KPK, Pakistan
8. Department of Biotechnology, The Islamia University of Bahawalpur, Bahawalpur, Pakistan

CERTIFICATES/TRAININGS QUALIFIED

1. “Certificate of Service” by National Cadet Corps, Multan. December 01, 1994 - December 18, 1995.
2. “Certificate in Children Health” by Islamabad Paramedical Institute, Islamabad. July 01- August 31, 2003.
3. “Postgraduate Training Course (Research Techniques)” by Pakistan Atomic Energy Commission, NIAB Faisalabad. September 20 - October 01, 2004.
4. “Training Course (Safety Measures in use of Radiation)” Pakistan Atomic Energy Commission, NIAB Faisalabad. December 20 - December 24, 2004.
5. “Postgraduate Training Course (Diseases of Chest & Heart)” King Edward Medical College, Pakistan Chest Foundation, Lahore. January 31 – February 12, 2005.
6. “6 Physician Cases for Pain Treatment” Albert Einstein College of Medicine, New York. August 10, 2006.
7. “Depression in the Elderly: Clinical Manifestations, Treatment Safety, and Comorbidity” by American Association for Geriatric Psychiatry; on June 28, 2006.
8. “Complimentary Bioterrorism Course” by American Board of Quality Assurance and Utilization Review Physicians, Inc.; on August 03, 2006.
9. “New Trial Results on the Risk/Benefit of Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease” by Baylor College of Medicine, Texas; on July 01, 2006.
10. “Vulvodynia - Focus on Recognition and Management” by Baylor College of Medicine, Texas; on July 08, 2006.
11. “Recommendations for Estrogen and Progestogen Use in Peri- And Postmenopausal Women: October 2004 Position Statement of the North American Menopause Society” by Baylor College of Medicine, Texas; on July 25, 2006.

12. "Maximizing Contraceptive Success" by Baylor College of Medicine, Texas; on August 02, 2006.
13. "Allergic Rhinitis - Pediatric Allergic Rhinitis" by Baylor Health Care System, Texas; on July 25, 2006.
14. "Maximizing Therapeutic Benefits in Breast Cancer" by Creative Educational Concepts, Inc.; on July 29, 2006.
15. "Giving Patients Options: HIV Risk Reduction Training for Clinicians" by Medcases, Inc. Philadelphia; on August 10, 2006.
16. "New Development in HIV Drug Resistance and Options for Treatment-Experience Patients" by Medical Education Collaborative; on July 07, 2006.
17. "Advances in Lung Cancer Therapy: 2005" by Meniscus Educational Institute; on August 15, 2006.
18. "Applying Best Practices to Reduce Infection Rates in The Critical Care Setting" by Meniscus Educational Institute; on August 21, 2006.
19. "Symptom Management in Cancer: Pain, Depression and Fatigue" by National Institute of Health, USA; on July 8, 2006.
20. "Breast Cancer Staging" by The American Cancer Society; July 25, 2006.
21. "NSAID-Induced GI Toxicity" by The American Gastroenterological Association Institute; on July 29, 2006.
22. "Early Diagnosis & Management of Carcinoid Tumors" by The American Gastroenterological Association Institute; August 02, 2006.
23. "Treatment Termination Case" by The Chatham Institute; on July 25, 2006.
24. "Medicine Today: Internal Medicine: Depression" by The Cleveland Clinic Foundation; on July 03, 2006.
25. "Clinical Decisions: Dementia" by The Cleveland Clinic Foundation; on August 08, 2006.
26. "New Advances in the Diagnosis and Management of Vaginal Infections" by The Dannemiller Memorial Educational Foundation, Texas; on August 03, 2006.
27. "New Treatment Options for Psoriasis Involving the Hands and Feet" by The Dannemiller Memorial Educational Foundation, Texas; on August 08, 2006.
28. "A 60-Year-Old Woman with Diabetes and Leg Pain" by The Discovery Institute of Medical Education, Chicago; on July 01, 2006.
29. "Targeting Abdominal Obesity to Reduce Cardiovascular Risk in Patients with Type 2 Diabetes" by The Discovery Institute of Medical Education, Chicago; on July 01, 2006.

30. "Laboratory Monitoring of Coagulation" by The FCG Institute for Continuing Education; on August 15, 2006.
31. "Insomnia and Psychiatric Disorders" by The Johns Hopkins University, School of Medicine; on August 15, 2006.
32. "Human Papillomavirus (HPV) and Management of Abnormal PAP Tests" by The University of Kentucky, College of Medicine; on August 10, 2006.
33. "Issues & Therapeutic Options in the Management of Healthcare-Associated Pneumonia" by The University of Kentucky, College of Medicine; on August 10, 2006.
34. "Evidence-Based Therapies for Migraine Headache" by The University of Kentucky, College of Medicine; on August 17, 2006.
35. "Hepatitis C" by The University of Nebraska; on June 28, 2006.
36. "A 63-Year-Old Woman with Lower Limb Swelling and Pain" by The University of Nebraska; on July 07, 2006.
37. "Atherosclerosis" by The University of Nebraska; on August 12, 2006.
38. "Changing concepts in management of HIV disease" by School of Medicine, University of Alabama, USA; July 04, 2006
39. "Natural history and epidemiology of HPV" by American Society for Coloscopy and Cervical Pathology; August, 2006
40. "Gene Therapy Protects Against Diabetic Nerve Damage" by The University of Pennsylvania, School of Medicine; on July 13, 2006.
41. "Parkinson's Gene Therapy Promising In Early Trial Results" by The University of Pennsylvania, School of Medicine; on July 13, 2006.
42. "Anti-HIV Therapy for Kids Prevents Opportunistic Infections" by The University of Pennsylvania, School of Medicine; on July 22, 2006.
43. "Thrombin Test Detects Low Risk of Recurrent Blood Clots" by The University of Pennsylvania, School of Medicine; on July 29, 2006.
44. "High Blood Pressure Lowers Walking Ability in Elderly" by The University of Pennsylvania, School of Medicine; on August 03, 2006.
45. "Carcinogenic HPV Variants Play the Race Card" by The University of Pennsylvania, School of Medicine; on August 03, 2006.
46. "Fetal Alcohol & Women" by The University of Wisconsin, School of Medicine and Public Health; on July 11, 2006.
47. "Clinical Focus on Anemia Management in Breast Cancer Patients" by The University of Wisconsin, School of Medicine and Public Health; on July 13, 2006.

48. "Prevention of Radiation Induced Proctosigmoiditis" by The University of Texas; on August 15, 2006.
49. "Renal Stones" by Thomson American Health Consultants, Georgia; on July 03, 2006.
50. "Prostate Cancer Prevention: What And What Not To Tell Your Patients" by Thomson American Health Consultants, Georgia; on July 25, 2006.
51. "Giant Cell Arteritis: Diagnosing and Treating Inflammatory Disease in Older Adults" by Thomson American Health Consultants, Georgia; on July 25, 2006.
52. "Changing Concepts in the Management of HIV Disease" by University of Alabama, School of Medicine; on July 4, 2006.
53. "Evaluation of Hyperlipidemia" by University of Alabama, School of Medicine; on July 4, 2006.
54. "Management of Atrial Fibrillation Study Results May Alter Treatment Approaches" by University of Alabama, School of Medicine; on July 25, 2006.
55. "Bioterrorism Practice" by University of Alabama, School of Medicine; on July 25, 2006.
56. "Why an Electronic Health Record (EHR) for my Practice?" by University of Alabama, School of Medicine; on August 03, 2006.
57. "Applying Research to Clinical Practice in the Treatment of Alcohol Dependence: The Evolving Role of Pharmacotherapy" by University of Medicine and Dentistry of New Jersey; on July 01, 2006.
58. "Basic Abdominal Sonographic Anatomy and Protocol" by Society of Diagnostic Medical Sonography, USA; on July 08, 2006.
59. "First Biennial Course (Chemical Pathology and Endocrinology)" by Armed Forces Institute of Pathology, Rawalpindi; August 18 – August 20, 2006.
60. "Training Course (Molecular Medicine & Drug Research)" by COMSTECH, Islamabad; January 16 – January 30, 2007.
61. "Training Course (Biosecurity/Food Safety Enhancement Program)" by Quaid-i-Azam University, Islamabad; February 01 – March 31, 2008.
62. "Introduction to Good Clinical Practices" by Physis Learning Academy - Faculty of Health Sciences; July 18, 2014.
63. Professional Development Training (English for Academic Purposes)" by Bahauddin Zakariya University, Multan/ HEC, Islamabad; October 11 – October 13, 2017.
64. Training "Dynamic teaching skills" by Bahauddin Zakariya University, Multan/ ORIC, BZU; March 28, 2018.

RELIGIOUS CERTIFICATE COURSES

Taleem-ul-Quran, Lahore

- | | |
|--|----------------|
| 1. Religious course with certificate of “ Sanad-e-Izaz ” | February, 1992 |
| 2. Religious course with certificate of “ Sanad-e-Imtiaz ” | May, 1992 |
| 3. Certificate course on “ Salutation ” | January, 1993 |
| 4. Certificate course on “ System of Justice and Censures ” | February, 1995 |

WORKSHOPS, CONFERENCES & SEMINARS

1. Workshop on “**e-Journals and Digital Library**” held on July 20-21, 2004; organized by DRSM Library, Quaid-I-Azam University, Islamabad and Higher Education Commission, Islamabad.
2. “**First National Conference of Pakistan Society of Chemical Pathologists**” held on February 25-26, 2005; at King Edward Medical College, Lahore.
3. Workshop on “**Laboratory Accreditation**” held on February 24, 2005; organized by Pakistan Society of Chemical Pathologists at King Edward Medical College, Lahore.
4. **Member of Organizing Committee** for “**Seminar on Herbal Drugs and Industry in Pakistan**” held on September 23-24, 2005; organized by Riphah International University in collaboration with HEJ Research Institute, Karachi.
5. “**International Workshop for Physical Therapy**” held on December 13-14, 2005 at Shifa International Hospital, Islamabad.
6. “**International Workshop on Current Advances in Gene Therapy**” held on April 02-10, 2007 at COMSTECH, Islamabad.
7. “**DNA Fragmentation by Bio-Molecular Techniques**” held on January 11-14, 2010 at Department of Zoology, GC University, Faisalabad.
8. “**First National Pharmacy ZFB Symposium, BZU**” held on April 21, 2011 at College of Pharmacy, GC University, Faisalabad.
9. Workshop on “**Rational Emotive Behavior Therapy**” held on May 26, 2012; organized by Department of Applied Psychology, GC University, Faisalabad.
10. Seminar on “**Bioethics**” held on June 27, 2012; organized by Faculty of Science and Technology & Directorate of Medical Sciences, GC University, Faisalabad.
11. Workshop on “**Research Methodologies & Effective Publication Practices**” held on December 12-14, 2012; organized by College of Computer Science & Information Studies, GC University, Faisalabad.
12. Seminar on “**Career Counseling**” held on June 06, 2013 at College of Pharmacy, GC University, Faisalabad.
13. Seminar on “**Pharma Industry Contribution for Diabetes Management and Career Development**” held on September 11, 2013 at College of Pharmacy, GC University, Faisalabad.
14. Seminar on “**Nano-particles and Herbal Medicine**” held on December 04, 2013 at College of Pharmacy, GC University, Faisalabad.

15. Seminar on “**Legal issues: Pharmacy Profession in Saudi Arabia**” held on March 19, 2014 at College of Pharmacy, GC University, Faisalabad.
16. “**Orientation & Biosafety Workshop**” held on October 13, 2015 at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
17. “**Basic Bioinformatics**” three days workshop held on April 19-21, 2016 at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
18. “**Intellectual Property Rights and Patent Drafting**” one day workshop held on May 11, 2016 at Faculty of Veterinary Sciences, Bahauddin Zakariya University, Multan.
19. “**Expanding Eastern Medicine for Health of All**” one day seminar held on November 10, 2016 at Faculty of Pharmacy, Bahauddin Zakariya University, Multan.
20. “**The Role of Faculty in the Protection of Human Values & Conflict Management in Muslim Society**” three-day workshop held on August 16-18, 2017 at Department of Islamic Studies, Bahauddin Zakariya University, Multan.
21. “**Exploring New Avenues for Pharmacy Profession**” two days International Pharmaceutics Conference held on February 12-13, 2018 at Department of Pharmaceutics, Bahauddin Zakariya University, Multan.
22. “**Postgraduate Symposium 2018**” held on 24th April and organized by Zakariyan Federation of Biotechnologists, Bahauddin Zakariya University, Multan.

MEMBERSHIPS OF SOCIETIES/COUNCILS

1. Registered Pharmacist (RPh), Punjab Pharmacy Council, Lahore.
2. Registered Homeopathic Medical Practitioner (RHMP), National Council for Homeopathy, Islamabad.
3. Member, International Chemical Biology Society (ICBS)
4. Member, Asian Federation of Biotechnology (AFOB)
5. Member, American Society for Microbiology (ASM)
6. Member, European Federation of Biotechnology (EFB)
7. Member, The Society for the Advancement of Science (Africa) (SASA)
8. Member, Hong Kong Biotechnology Organization (HKBO)
9. Member, Commonwealth Pharmacists Association (CPA)
10. Member, Zakarian Federation of Biotechnologists (ZFB)
11. Member, American Pharmacists Association (APhA)
12. Member, Association for Middle Level Education (AMLE)
13. Member, Canadian Society of Biochemistry, Molecular & Cellular Biology
14. Member, Canadian Society for Molecular Biosciences (CSMB)
15. Member, Friends of the Trees Society (FTS)
16. Member, The Herb Society (HB)
17. Member, International Natural Hygiene Society (INHS)

18. Member, The Association of Applied Biologists (AAB)
19. Member, National Academy of Young Scientists (NAYS)
20. Member, Bioinformatics Organization
21. Member, Australian and New Zealand Mental Health Association
22. Member, Pharmaceutical Society of Australia (PSA)
23. Member, International Association of Engineers (Genetic Engineer)
24. Member, American Society for Pharmacology & Experimental Therapeutics (ASPET)
25. Member, Nonihal Book Club, Karachi
26. Member, Hukma Organization Council, Lahore
27. Member, Health, Education, Applications, Research, Training Society, Islamabad
28. Member, Society for Health, Education & Development (SHED), Islamabad
29. Member, International Dermoscopy Society (IDSS), Italy.

EDITORSHIP

A. Editor/Associate Editor:

1. Frontiers in Medicine
ISSN: 2296-858X; <https://loop.frontiersin.org/people/432504/editorial>
2. The Pharma Innovation Journal
ISSN: 2349-8242; <http://www.thepharmajournal.com/board.php>

B. Member Editorial/Review Board:

1. Journal of AIDS and HIV Research
ISSN: 2141-2359; www.academicjournals.org/JAHR
2. International Journal of Medical Studies
ISSN 2542-2766; <http://www.brainybuzz.in/journal/index.php/ijms>
3. Asian Journal of Natural & Applied Sciences
ISSN: 2186-8468; <http://www.ajsc.leena-luna.co.jp/>
4. International Journal of Universal Pharmacy and Life Sciences
ISSN: 2249 –6793; <http://www.ijupls.com>
5. Academic Research International
ISSN: 2223-9553; <http://www.journals.savap.org.pk>
6. International Journal of Pediatrics and Child Health
ISSN: 2311-8687; <http://savvysciencepublisher.com>
7. The Open Access Journal of Science and Technology
ISSN: 2314-5234; <http://www.oajost.com>
8. Journal of Agricultural Research and Innovative Technologies

- ISSN 2505-1059; <http://www.brainybuzz.in/journal/index.php/jarit>
9. Pharmaceutical and Biomedical Research
ISSN: 2423-4446; <http://pbr.mazums.ac.ir/>
10. Journal of Rashid Latif Medical College
<http://www.jrlmc.com>
11. Journal of Biology, Life Science and Scientific Research
ISSN 2505-1032; <http://www.brainybuzz.in/journal/index.php/jblssr>
12. The Open Access Journal of Science and Technology
ISSN: 2314-5234; <http://www.oajost.com>
13. American Journal of Clinical and Experimental Medicine
ISSN: 2330-8133; <http://www.sciencepublishinggroup.com/j/ajcem>
14. Journal of Pharmaceutical Research and Regulatory Affairs
ISSN 2505-1016; <http://www.brainybuzz.in/journal/index.php/jprra>
15. Journal of Economic Research and Studies
ISSN 2505 -1024; <http://www.brainybuzz.in/journal/index.php/jers>

C. Reviewed more than 250 articles mostly for Impact Factor Journals

DISTINCTIONS/AWARDS

Declared as **THE TOP SCIENTIST** (Number 1) among pharmaceutical scientists of Pakistan by the Pakistan Council for Science and Technology (Ministry of Science and Technology), Pakistan for Research Productivity Award (2017)

- Productive Scientist of Pakistan (2010) Pakistan Council for Science and Technology
- Research Productivity Award (2011) Pakistan Council for Science and Technology
- Top 100 Educator (2012) International Biographical Centre, Cambridge, England
- American Order of Merit (2012) American Biographical Institute, USA
- Research Productivity Award (2012) Pakistan Council for Science and Technology
- 2000 Outstanding Intellectuals of the 21st Century (2013) International Biographical Centre, Cambridge, England
- Performance Based Increment (2014) Bahuddin Zakariya University, Multan
- Performance Based Honorarium (2014) Bahuddin Zakariya University, Multan
- Research Productivity Award (2015) Pakistan Council for Science and Technology
- Productive Scientist of Pakistan (2015) Pakistan Council for Science and Technology
- Performance Based Increment (2015) Bahuddin Zakariya University, Multan
- Performance Based Honorarium (2015) Bahuddin Zakariya University, Multan

- Best Young Research Scholar (2016) Higher Education Commission, Pakistan
- Productive Scientist of Pakistan (2016) Pakistan Council for Science and Technology
- Research Productivity Award (2016) Pakistan Council for Science and Technology
- Performance Based Increment (2016) Bahuddin Zakariya University, Multan
- Performance Based Honorarium (2016) Bahuddin Zakariya University, Multan
- Productive Scientist of Pakistan (2017) Declared as The Top Most Scientist (Number 1) among pharmaceutical scientists of Pakistan (under 40) by the Pakistan Council for Science and Technology (Ministry of Science and Technology), Pakistan
- Research Productivity Award (2017) Pakistan Council for Science and Technology
- Performance Based Increment (2017) Bahuddin Zakariya University, Multan
- Performance Based Honorarium (2017) Bahuddin Zakariya University, Multan

PATENTS

1. **Qadir MI**, Chauhdary Z. Qadirphages (local bacteriophages) against *Escherichia coli*, *Pseudomonas aeruginosa* and *Streptococcus pneumonia*. (IPO-Pakistan, No. 381/2014)
2. **Qadir MI**, Nazish A. Qadirphages (local bacteriophages) against *Staphylococcus aureus*, methicillin-resistant *Staphylococcus aureus* (MRSA) and *Bacillus cereus*. (IPO-Pakistan, No. 382/2014)
3. **Qadir MI**, Ali M, Nazish A. Synergistic phage preparations: Qadir *Sauvan*, Qadir *Mrsavan* and Qadir *Bcevan*. (IPO-Pakistan, No. 686/2014)
4. **Qadir MI**, Chauhdary Z, Ali M. Synergistic phage preparations: Qadir *Ecoamp*, Qadir *Paeamp* and Qadir *Spnamp*. (IPO-Pakistan, No. 687/2014)

PUBLICATIONS

ISI INDEXED (Cumulative Impact Factor: ~ 110)

1. **Qadir MI**, Malik SA, Naveed AK and Ahmad I (2006) Plasma lipid profile in sarcoma patients. *Pak J Pharm Sci*, 19 (2): 155-158.
2. **Qadir MI**, Naveed AK, Ahmad I, Malik SA (2007) Plasma lipid profile in childhood non-Hodgkin lymphoma patients. *Pak Paed J*, 31(4): 167-70.
3. **Qadir MI**, Malik SA (2008) Plasma lipid profile in gynecologic cancers. *Europ J Gyne Oncol*, 29:158-161. (Impact Factor **0.641**)
4. Khalid SH, **Qadir MI**, Massud A, Ali M, Rasool MH (2009) Effect of degree of cross-linking on swelling and drug release behaviour of poly(methyl methacrylate-co-itaconic acid) [P(MMA/IA)] hydrogels for site specific drug delivery. *J Drug Delvr Sci Tech*, 19(6): 413-418. (Impact Factor **0.508**)
5. **Qadir MI**, Malik SA (2010) HIV fusion inhibitors. *Rev Med Virol*, 20: 23-33. (Impact Factor **5.6**)

6. **Qadir MI**, Malik SA, Tabassum N, Ali S, Nisar L (2010) Characterization of HR region of *gp41* of HIV. *Int J Agric Biol*, 12: 456-458. (Impact Factor **0.94**)
7. Masood MI, **Qadir MI**, Shirazi JH, Khan IU (2011) Beneficial effects of lactic acid bacteria on human beings. *Critical Rev Micro*, 37(1): 91–98. (Impact factor **6.27**)
8. **Qadir MI**, Malik SA (2011) Genetic variation in the HR region of the *env* Gene of HIV: A perspective for resistance to HIV fusion inhibitors. *AIDS Res Hum Retrovir*, 27(1): 57-63. (Impact factor **2.246**)
9. Javed F, **Qadir MI**, Janbaz KH, Ali M (2011). Novel drugs from marine microorganisms. *Critical Rev Micro*, 37(3): 245–249. (Impact factor **6.27**)
10. Hussain A, Khalid SH, **Qadir MI**, Massud A, Ali M, Khan IU, Saleem M, Iqbal MS, Asghar S, Gul H (2011) Water uptake and drug release behaviour of methyl methacrylate-co-itaconic acid [P(MMA/IA)] hydrogels cross-linked with methylene bis-acrylamide. *J Drug Delvr Sci Tech*, 21(3): 249-255. (Impact Factor **0.679**)
11. Nisar L, **Qadir MI**, Malik SA, Tabassum N (2011) Characterization of the immunodominant regions within gp41 of *env* gene of HIV in Pakistan. *J Chem Soc Pak*, 33(4): 545-548. (Impact factor **1.377**)
12. **Qadir MI** (2011) Qadirvirtide. *Pak J Pharm Sci*, 24(4): 593-595. (Impact factor **1.103**)
13. Ahmad M, Mahmood Q, Gulzar K, Akhtar MS, Saleem M, **Qadir MI** (2012) Antihyperlipidaemic and hepatoprotective activity of *Dodonaea viscosa* leaves extracts in alloxan-induced diabetic rabbits (*Oryctolagus cuniculus*). *Pak Vet J*, 32(1):50-54. (Impact factor **1.365**)
14. Naz S, **Qadir MI**, Ali M, Janbaz KH (2012) Nanotechnology for imaging and drug delivery in cancer. *J Chem Soc Pak*, 34(1): 107-111. (Impact factor 1.377)
15. Ameen S, **Qadir MI**, Ahmad B (2012) Pharmacogenomic approaches in the treatment of breast cancer by tamoxifen. *Pak J Pharm Sci*, 25(2): 469-476. (Impact factor **0.947**)
16. Ehsan O, **Qadir MI**, Malik SA, Abbassi WS, Ahmad B (2012) Efficacy of nanogold-insulin as a hypoglycemic agent. *J Chem Soc Pak*, 34(2): 365-370. (Impact factor 1.377)
17. Janbaz KH, **Qadir MI**, Ahmad B, Sarwar A, Yaqoob N, Masood MI (2012). Tuberculosis – Burning issues: Multi-drug resistance and HIV-coinfection. *Critical Rev Micro*, 38(4): 267–275. (Impact factor **5.065**)
18. Amin N, **Qadir MI**, Khan TJ, Abbas G, Ahmad B, Janbaz KH, Ali M (2012) Antibacterial activity of Vacuum liquid chromatography (VLC) isolated fractions of chloroform extracts of seeds of *Achyranthes aspera*. *J Chem Soc Pak*, 34(3): 589-592. (Impact factor 1.377)
19. Janbaz KH, Nizsar U, Ashraf M, **Qadir MI** (2012) Spasmolytic, bronchodilator and antioxidant activities of *Erythrina superosa* Roxb. *Acta Pol Pharm*. 69(6): 1111-1117. (Impact factor **0.665**)
20. Usman M, Ashraf M, Ashiq B, Khokhar MI, Masood MI, Afzal S, Omer O, Ali M, **Qadir MI** (2013) Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid fever. *Iranian J Pharm Res*. 12(1): 147-154. (Impact factor **0.51**)

21. Janbaz KH, Jan A, **Qadir MI**, Gilani AH (2013) Spasmolytic, bronchodilator and vasorelaxant activity of methanolic extract of *Tephrosia purpurea*. *Acta Pol Pharm*, 79(2): 261-269. (Impact factor **0.693**)
22. Janbaz KH, **Qadir MI**, Jan A, Gilani AH (2013) Anti-diarrheal activity of methanolic extract of *Tephrosia purpurea*. *Acta Pol Pharm*, 79(2): 345-347. (Impact factor **0.693**)
23. Ali M, **Qadir MI**, Saleem M, Janbaz KH, Gul H, Hussain L, Ahmad B (2013) Hepatoprotective potential of *Convolvulus arvensis* against paracetamol-induced hepatotoxicity. *Bangladesh J Pharmacol*, 8: 300-304. (Impact factor **0.514**)
24. Bokhari TH, Hina S, Ahmad M, Iqbal M, Shafiq M, Arshad MN, Asghar MN, Aslam M, **Qadir MI** (2013) Concentration of ¹⁸⁸Re-Perrhenate for Therapeutic Radiopharmaceuticals. *J Chem Soc Pak*, 35(1): 147-150. (Impact factor **0.612**)
25. Farooqi AA, Butt G, Yousaf G, **Qadir MI**, Shaukat U, Mansoor Q, Awan M, Bhatti S, Begum A (2013) Making personalized prostate cancer medicine a reality: Challenges and opportunities in the re-establishment of gold standards. *Pak J Pharm Sci*, 26(4): 831-840. (Impact factor **0.95**)
26. Abbas G, Hussain A, Abbas G, Rasool S, Ali MY, Ali A, Bokhari TH, Hameed S, **Qadir MI**, Ahmad B (2013) Development of biofertilizer from sugar industry organic waste. *J Chem Soc Pak*, 35(2): 415-419. (Impact factor **0.612**)
27. Saleem M, **Qadir MI**, Perveen N, Ahmad B, Saleem U, Irshad T, Ahmad B (2013) Inhibitors of apoptotic proteins: New targets for anti-cancer therapy. *Chem Biol Drug Des*, 82: 243-251. (Impact factor **2.507**)
28. Azam F, **Qadir MI**, Uzair M & Ahmad B (2013) Evaluation of antibacterial and antifungal activity of *Ficus carica* and *Cassia fistula*. *Lat Am J Pharm*. 32 (9): 1412-4. (Impact factor 0.319)
29. Iqbal MZ, **Qadir MI**, Mallhi TH, Khan YH, Ahmad B (2014) Probiotics and their beneficial effects against various diseases. *Pak J Pharm Sci*, 27(2): 405-415. (Impact factor **0.682**)
30. Mallhi TH, **Qadir MI**, Khan YH, Ali M (2014) Hepatoprotective activity of aqueous methanolic extract of *Morus nigra* against paracetamol-induced hepatotoxicity in mice. *Bangladesh J Pharmacol*, 9: 60-66. (Impact factor **1.052**)
31. Janbaz KH, Hamid I, Gilani AH, **Qadir MI** (2014). Spasmolytic, bronchodilator, and vasodilator activities of aqueous-methanolic extract of *Ocimum basilicum*. *Int J Agric Biol*, 16: 321–327. (ISI Indexed)
32. Mallhi TH, **Qadir MI**, M. Ali, Ahmad B, Khan YH, Rehman AU (2014) Ajwa Date (*Phoenix dactylifera*): An emerging plant in pharmacological research. *Pak J Pharm Sci*, 27(3): 607-616. (Impact factor **0.682**)
33. **Qadir MI**, Murad MSA, Ali M, Saleem M, Farooqi AA (2014) Hepatoprotective effect of leaves of aqueous ethanol extract of *Cestrum nocturnum* against paracetamol-induced hepatotoxicity. *Bangladesh J Pharmacol*, 9: 167-170. (Impact factor **1.052**)
34. Saleem M, Ahmed B, **Qadir MI**, Mahrukh, Rafiq M, Ahmad M, Ahmad B (2014) Hepatoprotective effect of *Chenopodium murale* in mice. *Bangladesh J Pharmacol*, 9: 124-128. (Impact factor **1.052**)

35. Saleem M, Karim M, **Qadir MI**, Ahmad B, Rafiq M, Ahmad B (2014) *In vitro* antibacterial activity and phytochemical analysis of hexane extract of *Vicia sativa*. *Bangladesh J Pharmacol*, 9: 189-193. (Impact factor **1.052**)
36. **Qadir MI**, Ali M, Ali M, Saleem M, Hanif M (2014) Hepatoprotective activity of aqueous methanolic extract of *Viola odorata* against paracetamol-induced liver injury in mice. *Bangladesh J Pharmacol*, 9: 198-202. (Impact factor **1.052**)
37. Parveen A, Akash MSH, Rehman K, Mahmood Q, **Qadir MI** (2014) Analgesic, anti-inflammatory and anti-pyretic activities of *Caesalpinia decapetala*. *BioImpacts*, 4(1): 43-48. (ISI Indexed)
38. Hanif M, Shoaib MH, Yousuf RI, Sattar S, Nadeem M, Hussain L, Zia MU, Muhammad IN, Uzair M, **Qadir MI** (2014) Formulation development of intermediate release Nimesulide tablets by CCRD for IVIVC studies. *Pak J Pharm Sci*, 27(4): 785-792. (Impact factor **0.682**)
39. Janbaz KH, **Qadir MI**, Basser HT, Bokhari TH, Ahmad B (2014) Risk for oral cancer from smokeless tobacco. *Contemp Oncol*, 18(3): 160-164. (ISI Indexed)
40. Khalid M, Bokhari TH, Ahmad M, Bhatti HN, Iqbal M, Ghaffar A, **Qadir MI** (2014) Evaluation of carrier added and no carrier added ^{90}Y -EDTMP as bone seeking therapeutic radiopharmaceutical. *Pak J Pharm Sci*, 27(4): 813-818. (Impact factor **0.682**)
41. Saleem M, **Qadir MI**, Ahmad B, Saleem U, Naseer F, Schini-Kerth V, Ahmad M, Hussain K (2014) Cytotoxic effect of ethanol extract of *Convolvulus arvensis* L (Convolvulaceae) on lymphoblastic leukemia Jurkat cells. *Trop J Pharm Res*, 13(5): 705-709. (Impact factor **0.589**)
42. Saleem M, Ahmed B, Karim M, Rafiq M, Ahmad S, Ahmad M, **Qadir MI**, Syed MH (2014) Hepatoprotective effect of *Rumex dentatus* in paracetamol-induced hepatotoxicity in mice. *Bangladesh J Pharmacol*, 9(2): 284-289. (Impact factor **1.052**)
43. Mallhi TH, Abbas K, Ali M, **Qadir MI**, Khan YH (2014) Hepatoprotective activity of aqueous methanolic extract of *Malva parviflora* L. (Cheeseweed Mallow) against Paracetamol induced hepatotoxicity in mice. *Bangladesh J Pharmacol*, 9: 342-346. (Impact factor **1.052**)
44. **Qadir MI**, Abbas K, Hamayun R, Ali M (2014) Analgesic, anti-inflammatory and anti-pyretic activities of aqueous ethanolic extract of *Tamarix aphylla* L. (Saltcedar) in mice. *Pak J Pharm Sci*, 27(6): 1985-1988. (Impact factor **0.682**)
45. **Qadir MI**, Ali M, Ibrahim Z (2014) Anticancer activity of *Morus nigra* leaves extract. *Bangladesh J Pharmacol*, 9(4): 496-497. (Impact factor **1.052**)
46. Hussain L, **Qadir MI**, Rehman S (2014) Antihyperglycemic and hypolipidemic potential of *Caesalpinia decapetala* in alloxan-induced diabetic rabbits. *Bangladesh J Pharmacol*, 9(4): 529-532. (Impact factor **1.052**)
47. Farooqi AA, Attar R, Arsalan BA, Romero MA, Haq MF, **Qadir MI** (2014) Recently emerging signaling landscape of ataxia-telangiectasia mutated (ATM) kinase. *Asian Pac J Cancer Prev*, 15(16): 6485-8. (Impact factor **2.514**)
48. **Qadir MI** (2015) Phage therapy: A modern tool to control bacterial infections. *Pak J Pharm Sci*, 28(1): 265-270. (Impact factor **0.581**)

49. **Qadir MI**, Abbas K, Tahir M, Irfan M, Bukhari SFR, Ahmed B, Hanif M, Rasul A, Ali M (2015) Dengue fever: Natural management. *Pak J Pharm Sci*, 28(2): 647-655. (Impact factor **0.581**)
50. Saleem M, Abbas K, Manan M, Ijaz H, Ahmed B, Ali M, Hanif M, Farooqi AA, **Qadir MI** (2015) Epigenetic therapy for cancer. *Pak J Pharm Sci*, 28(3): 1023-1032. (Impact factor **0.581**)
51. Gul H, Abbas K, **Qadir MI** (2015) Gastro-protective effect of ethanolic extract of *Mentha longifolia* in alcohol & aspirin induced gastric ulcer models. *Bangladesh J Pharmacol*, 10(1): 241-245. (Impact factor **0.671**)
52. **Qadir MI**, Ali M, Muhammad SA, Hanif M, Farooqi AA, Abbas R (2015) HIV-associated osteoporosis. *Rev Med Micro*, 26(1): 14-19.
53. Paracha UZ, Hayat K, Ali M, **Qadir MI** (2015) New diagnostic and therapeutic avenues for mesothelioma. *Pak J Pharm Sci*, 28(4): 1425-32. (Impact factor **0.581**)
54. **Qadir MI**, Maqbool F, Ali M (2015) HIV-*Plasmodium* Co-infection: Malaria in AIDS patients. *Pak J Pharm Sci*, 28(5): 1811-17. (Impact factor **0.581**)
55. **Qadir MI**, Perveen A, Ali M (2015) Cdc42: Role in cancer management. *Chem Biol Dru Des*, 86: 432–439. (Impact factor **2.802**)
56. Mallhi TH, Sarrieff A, Adnan AS, Khan YH, **Qadir MI**, Hamzah AA, Khan AH (2015) Effect of Fruit/Vegetable-Drug Interactions on CYP450, OATP and p-Glycoprotein. *Trop J Pharm Res*, 14(10): 1927-1935. (Impact factor **0.543**)
57. Massud A, Ishfaq B, Ahmed B, **Qadir MI** (2015) Formulation, development and optimization of propranolol mucoadhesive bilayer tablets by using central composite design and its *in-vitro* studies. *Lat Am J Pharm*, 34(8): 1637-44. (Impact factor **0.329**)
58. **Qadir MI** (2016) Qadir test. *Pak J Pharm Sci*, 29(1): 247-248. (Impact factor **0.649**)
59. **Qadir MI**, Abbas K, Qadeer K, Abid A (2016) AIDS related malignancies. *Rev Med Micro*, 27(1): 1-8.
60. **Qadir MI**, Arooj J (2016) Advantage of pegylated interferon and ribavirin combination therapy in people living with HCV/HIV co-infection. *Rev Med Micro*, 27(1): 9-12.
61. Afzal S, Chaudhry BA, Saeed J, Afzal K, Ahmed B, **Qadir MI** (2016) Antibacterial and antioxidant activity of methanolic extract of *Zaleya pentandra*. *Acta Pol Pharm*, 73(1): 147-151. (Impact factor **0.745**).
62. **Qadir MI**, Perveen A, Abbas K, Ali M (2016) Analgesic, anti-inflammatory and antipyretic activities of *Thymus linearis*. *Pak J Pharm Sci*, 29(2): 591-594. (Impact factor **0.649**)
63. **Qadir MI** (2016) Skin cancer: etiology and management. *Pak J Pharm Sci*, 29(3): 999-1003. (Impact factor **0.649**)
64. Lin X, Aslam A, Attar R, Yaylim I, Qureshi MZ, Hasnain S, **Qadir MI**, Farooqi AA (2016) Signaling landscape of prostate cancer. *Cell Mol Biol*. 62 (1): 45-50. (Impact factor **0.920**)
65. Mannan M, Hussain L, Ijaz H, **Qadir MI** (2016) Antimicrobial activity of *Kalanchoe laciniata*. *Pak J Pharm Sci*, 29(4): 1321-1324. (Impact factor **0.649**)

66. **Qadir MI**, Naqvi STQ, Muhammad SA (2016) Curcumin: a polyphenol with molecular targets for cancer control. *Asian Pac J Cancer Prev*, 17(6): 2735-2739. (Impact factor -)
67. Irfan M, Akram A, Zahoor AF, **Qadir MI**, Hussain A, Abbas N, Khan A, Arshad MS & Khan NI (2016) Formulation parameters affecting floating behaviour and drug release from extended release floating tablets of ranitidine hydrochloride. *Lat Am J Pharm*. 35(sup 1): 1206-16. (Impact factor **0.298**)
68. Fatima N, Mumtaz A, Shamim R, **Qadir MI**, Muhammad SA (2016). *In-silico* analyses of epicoccamides on selected *Leishmania* trypanothione reductase enzyme-based target. *Ind J Pharm Sci*. 78(2):259-266. (Impact factor **0.660**)
69. **Qadir MI**, Abbas K, Younus A, Shaikh RS (2016) Antibacterial activity of sea buckthorn (*Hippophae rhamnoides* L.) against methicillin resistant *Staphylococcus aureus* (MRSA). *Pak J Pharm Sci*, 29(5): 1705-1707. (Impact factor **0.649**)
70. Asif U, Sherwani AK, Akhtar N, Shoaib MH, Hanif M, **Qadir MI**, Zaman M (2016) Formulation development and optimization of febuxostat tablets by direct compression method. *Adv Polym Technol*. 35(2): 129-135. (Impact factor **1.291**)
71. **Qadir MI**, Rehman AU, Akash MSH, Irfan M, Baber M, Hussain SB (2016) Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome. *Pak J Pharm Sci*, 29(6): 2103-2104. (Impact factor **0.649**)
72. Irfan M, Rabel S, Bukhtar Q, **Qadir MI**, Jabeen F, Khan A (2016) Orally disintegrating films: A modern expansion in drug delivery system. *Saudi Pharmaceutical J*. 24, 537–546. (Impact factor **2.302**)
73. Farooq T, Hameed A, Rehman K, Ibrahim M, **Qadir MI**, Akash MSH (2016) Antiretroviral agents: looking for the best possible chemotherapeutic options to conquer HIV. *Crit Rev Eukaryot Gene Expr*. 26(4):363-381. (Impact factor **1.599**)
74. Hussain L, Abbas K, Ahmed B, Baber M, Muhammad SA, **Qadir MI** (2017) Analgesic and anti-inflammatory activity of aqueous-methanolic extract of *Aerva javanica*. *Pak J Pharm Sci*, 30(1): 213-215. (Impact factor 0.649)
75. Hussain L, Ain NU, Akash MSH, Iqbal R, Irfan M, **Qadir MI** (2017) Analgesic, anti-inflammatory and antipyretic activity of *Salvia moorcroftiana*. *Pak J Pharm Sci*, 30(2): 481-486. (Impact factor 0.649)
76. **Qadir MI**, Ahmed Z (2017) *lep* expression: Role in obesity and diabetes type 2. *Crit Rev Eukaryot Gene Expr*. 27(1): 47–51. (Impact factor 1.599)
77. **Qadir MI**, Abid A (2017) Acute HIV infection: advances in mechanism and prophylactic therapeutic management. *Crit Rev Eukaryot Gene Expr*. 27(1): 79-90. (Impact factor 1.599)
78. Abbas K, Rizwani GH, Zahid H, **Qadir MI**, Ahmad MT (2017) Evaluation of nephroprotective activity of *Musa paradisiaca* L. in gentamicin-induced nephrotoxicity. *Pak J Pharm Sci*, 30(3): 881-890. (Impact factor 0.649)
79. Afzal S, Chaudhry BA, Afzal K, Saeed J, Akash SH, **Qadir MI**, (2017) Acetyl cholinesterase and butyryl cholinesterase inhibitory activities of *Zaleya pentandra*. *Acta Pol Pharm*, 74(3): 891-894. (Impact factor 0.745).

80. **Qadir MI**, Ahmad Z (2017) Advances in hepatoprotective medicinal plants research. *Bangladesh J Pharmacol*, 12: 229-242. (Impact factor 0.616)
81. **Qadir MI**, Cheema BN (2017) Phytoestrogens and related food components in prevention of cancer. *Crit Rev Eukaryot Gene Expr.* 27(2): 99-112. (Impact factor 1.599)
82. **Qadir MI** (2017) Role of green tea flavonoids and related constituents in cancer prevention. *Crit Rev Eukaryot Gene Expr.* 27(2): 163-171. (Impact factor 1.599)
83. Afzal K, Uzair M, Chaudhry BA, Afzal S, Masood A, Saadullah M, **Qadir MI** (2017) Immunomodulatory, antiglycation and anti-ulcerative properties of *Ruellia squarrosa* Fenzl Acanthaceae. *Trop J Pharm Res.* 16(8):1751-1755. (Impact factor 0.569)
84. Bashir MF, **Qadir MI** (2017) Effect of ginger extract on angiogenesis using CAM assay. *Bangladesh J Pharmacol*, 12: 348-353. (Impact factor 0.616)
85. **Qadir MI**, Usman M, Akash MSH (2017) Transposable elements TEs (human endogenous retroviruses) in cancer. *Crit Rev Eukaryot Gene Expr.* 27(3): 219–227. (Impact factor 1.599)
86. **Qadir MI**, Zafar M (2017) TSG101: Tumor susceptibility gene 101 (*tsg101*) product - Role in therapy against HIV/AIDS. *Crit Rev Eukaryot Gene Expr.* 27(3): 237–246. (Impact factor 1.599)
87. **Qadir MI**, Faheem A (2017) miRNA: A diagnostic and therapeutic tool for pancreatic cancer. *Crit Rev Eukaryot Gene Expr.* 27(3): 197–204. (Impact factor 1.599)
88. Rehman K, Akash MSH, Liaqat A, KamalS, **Qadir MI**, Rasul A (2017) Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. *Crit Rev Eukaryot Gene Expr.* 27(3): 229–236. (Impact factor 1.599)
89. Ilyas U, Altaf R, Muhammad SA, **Qadir MI**, Nadeem H, Ahmed S (2017) Computational drug designing of newly synthesized triazoles against potential targets of methicillin resistant *Staphylococcus aureus*. *Pak J Pharm Sci*, 30(6): 2271-2279. (Impact factor 0.649)
90. **Qadir MI** (2017) Nanopreparations for better drug delivery. *Pak J Pharm Sci*, 30(6): 2301-2309. (Impact factor 0.649)
91. Butt G, Attar R, Tabassum S, Aras A, **Qadir MI**, Ozbey U (2017) Regulation of signal transduction cascades by Pterostilbenes in different cancers: Is it a death knell for oncogenic pathways. *Cellular & Molecular Biology*, 63(12): 5-10. (Impact factor 0.920)
92. **Qadir MI**, Anwar S (2017) Sirtuins in brain aging and neurological disorders. *Crit Rev Eukaryot Gene Expr.* 27(4): 321–329. (Impact factor 1.599)
93. **Qadir MI**, Sajjad S (2017) Phage therapy against *Streptococcus pneumonia*: Modern tool to control pneumonia. *Crit Rev Eukaryot Gene Expr.* 27(4): 289–295. (Impact factor 1.599)
94. **Qadir MI**, Rizvi SZ (2017) miRNA in hepatocellular carcinoma: Pathogenesis and therapeutic approaches. *Crit Rev Eukaryot Gene Expr.* 27(4): 355–361. (Impact factor 1.599)

95. **Qadir MI**, Hasan I, Mobeen T (2018) *In-silico* study of potential carboxylic acid derivatives as D-glutamate ligase inhibitors in *Salmonella typhi*. *Kuwait J Sci*. 45(1): 100-107. (Impact factor 0.811)
96. **Qadir MI** (2018) Hepatitis in AIDS Patients. *Rev Med Virol*. 28:e1956 (Impact factor 5.439)
97. **Qadir MI**, Manzoor A, Akash MSH (2018) Potential role of medicinal plants for anti-atherosclerosis activity. *Bangladesh J Pharmacol*, 13: 59-66. (Impact factor 0.616)
98. **Qadir MI**, Chuahday Z (2018) Antibacterial activity of novel strains of bactiophages: An experimental approach. *Crit Rev Eukaryot Gene Expr*. 28(1):1–12. (Impact factor 1.599)
99. **Qadir MI** (2018) Qadir theory of cancer etiology. *Crit Rev Eukaryot Gene Expr*. 28(1):13–15. (Impact factor 1.599)
100. Akbar MU, Rehman K, Zia KM, **Qadir MI**, Akash MSH, Ibrahim M (2018) Critical review on curcumin as a therapeutic agent: from traditional herbal medicine to an ideal therapeutic agent. *Crit Rev Eukaryot Gene Expr*. 28(1):17–24. (Impact factor 1.599)
101. Saleem S, Uzair M, Ahmad B, **Qadir MI**, Abbas K, Siddiqui FA, Qasir N (2018) Cytomorphological, phytochemical, antimicrobial and antioxidant investigations of different morphological parts of *Solanum xanthocarpum* Schrad & Wendl. *Lat Am J Pharm*. 37 (4): 839-848. (Impact factor **0.298**)
102. **Qadir MI**, Mobeen T (2018) Phage therapy: Progress in pharmacokinetics. *Braz J Pharm Sci*, 54(1):e17093. (Impact factor 0.616)
103. Imtiaz S, Ikram H, Ayaz M, **Qadir MI**, Muhammad SA (2018) Effect of glycine: Studying memory and behavioral changes in mice. *Pak J Pharm Sci*, 31(5): Published Online. (Impact factor 0.649)
104. **Qadir MI**, Hasan I (2018) Current management of higher levels of androgens: a new Hope for Hirsutism. *Pak J Pharm Sci*, 31(6): Published Online. (Impact factor 0.649)
105. Afzal S, Batool M, Chaudhary BA, Uzair M, Afzal K, **Qadir MI** (2018) Anticancer activity of roots of *Zaziphus mauritiana* against human breast cancer cell line. *Pak J Pharm Sci*, 31(6): Published Online. (Impact factor 0.649)
106. **Qadir MI**, Akash MSH, Irfan M, Ibrahim MR (2018) Importance of vitamin D in cancer management. *Pak J Pharm Sci*, 31(6): Published Online. (Impact factor 0.649)
107. **Qadir MI**, Irfan M, Zahoor AF, Syed KH, Khan IU, Hussain A, Arshad MS, Mohsin NA (2018). How to eliminate curing effect and improve storage stability of Eudragit® NE 30D coatings. *Lat Am J Pharm*. 37(0): Accepted. (Impact factor 0.319)

INTERNATIONAL

108. **Qadir MI** (2009) Medicinal and cosmetological importance of *Aloe vera*. *Int J Nat Ther*, 2: 21-26.

109. **Qadir MI**, Qureshi U (2010) Musculoskeletal pain treated by bisphosphonate therapy. *Inorganic Chem: Indian J*, 5(4): 2-6.
110. **Qadir MI**, Nian H (2010) A review on epilepsy and seizure. *Int J Med Res*, 1(1): 26-32.
111. **Qadir MI** (2010) Medicinal values of ginger. *Int J Nat Ther*, 3: 19-22.
112. Ilayas M, **Qadir MI** (2010) Role of estrogen in breast cancer. *Rev Pharmacol*, 2: 48-52.
113. Tabasum A, **Qadir MI** (2010) Deficiency of vitamin K linked to cancer, osteoporosis and heart diseases. *Int J Pharm Rev Res*, 1(1): 24-32.
114. **Qadir MI** (2010) A cheap method for diagnosis of cancer. *Pharmacologyonline*, Nl 3: 186-189.
115. Niaz M, **Qadir MI**, Niaz M (2010) Tumor markers for early detection of cancer. *Pharmacologyonline*, Nl 3: 628-633.
116. Mudassar S, **Qadir MI** (2010) Muscular dystrophy: an introduction. *Pharmacologyonline*, Nl 3: 669-672.
117. Akash MSH, Khan IU, Shah SNH, Asghar S, Massud A, **Qadir MI**, Akbar A (2010) Sustained release hydrophilic matrices based on xanthan gum and hydroxypropyl methylcellulose: development, optimization, in vitro and in vivo evaluation. *J App Pharm* 4 (2): 89-103.
118. Akram A, **Qadir MI** (2010) Parkinson's disease: causes and management. *Pharmacologyonline*, Nl 3: 673-676.
119. Munir S, **Qadir MI** (2010) Pathophysiology and management of pica. *Pharmacologyonline*, Nl 3: 677-681.
120. **Qadir MI**, Malik SA (2009) Effect of *Eugenia jambolana* leaves extracts on blood glucose levels of experimental diabetic rabbits. *Pharmacologyonline*, 3: 829-835.
121. **Qadir MI**, Malik SA (2010) Anti-diabetic activity of inorganic metals *Eugenia jambolana* Lam. (Myrtaceae) flowers. *Pharmacologyonline*, 2: 979-985.
122. **Qadir MI**, Munir I (2010) Gene therapy of cardiac failure. *J College Med Sci-Nepal*, 6(4): 69-75.
123. Shams I, **Qadir MI** (2010) Chocolate: good for health or not? *Pharmacologyonline*, Nl 2: 815-822.
124. **Qadir MI**, Hussain S (2010) Multi-drug resistant tuberculosis. *Res & Rev BioSci*, 4(4): 5-8.
125. **Qadir MI**, Mirza F (2010) Prevention of gastric cancer by *Helicobacter pylori* eradication: a review. *Pharmacologyonline*, Nl 3: 92-100.
126. **Qadir MI** (2010) An introduction to antibiotic production. *Pharmacologyonline*, Nl 3: 151-154.
127. **Qadir MI** (2010) Classification of diabetes mellitus. *Pharmacologyonline*, Nl 3: 155-160.
128. **Qadir MI**, Malik SA (2010) Comparison of alterations in red blood cell count and alterations in hemoglobin concentration in patients suffering from rectal carcinoma undergoing 5-fluorouracil and folic acid therapy. *Pharmacologyonline*, Nl 3: 240-

243.

129. Sabir S, **Qadir MI** (2010) Antidepressants: a critical review. *Pharmacologyonline*, *Nl* 3: 537-547.
130. Naeem A, **Qadir MI** (2010) Importance of exercise for diabetic patients. *Pharmacologyonline*, *Nl* 3: 624-627.
131. **Qadir MI**, Basser H, Shehwar D, Chaudhary F (2011) Awareness about ways of transmission of AIDS and its treatment among university students in Pakistan. *Ind J Pharm Pract*, 4(1): 33-35.
132. Saleem A, **Qadir MI** (2011) Future strategies in treatment of Alzheimer's disease. *Rev Pharmacol*, 4: 226-230.
133. Azam A, **Qadir MI** (2011) Strategies to manage thalassemia by gene therapy. *Rev Gene Therapy*, 1(1): 50-58.
134. Akhtar T, **Qadir MI** (2011) Advances in management of non-small cell lung cancer. *Rev Pharmacol*, 4: 233-241.
135. Asif MA, **Qadir MI** (2011) Molecular approaches for development of malarial vaccines. *Rev Pharmacol*, 4: 276-278.
136. **Qadir MI**, Saleem M, Khalid SH, Malik SA, Massud A, Ali M, Asghar S, Akash MSH (2011) Plasma lipid alterations in leukemia patients. *J App Pharm* 01(03): 159-164.
137. Mehvish S, **Qadir MI** (2011) Gene therapy for hepatocellular carcinoma. *Rev Gene Therapy*, 1(2): 11-21.
138. Khalid M, **Qadir MI** (2011) Suicide gene therapy. *Rev Gene Therapy*, 1(2): 36-42.
139. Rahman H, **Qadir MI** (2011) AIDS. *Health Sciences: International Journal*. 1(1):2-4.
140. Iqra J, **Qadir MI** (2011) Pathophysiology and management of myocarditis. *Pharmacologyonline* N, 1: 416-419.
141. Sayeb M, **Qadir MI** (2011) Schizophrenia: A Review. *Pharmacologyonline*, *Nl* 1: 420-423.
142. Irfan S, **Qadir MI** (2011) Management of hyperhidrosis. *Pharmacologyonline*, *Nl* 1: 424-427.
143. Maha Imtiaz, **Qadir MI** (2011) Management of irritable bowel syndrome. *J Adv Sci Res*, 2011; 2(2): 11-14.
144. Kakar MN, Masood MI, Janbaz KH, **Qadir MI**, Masood I, Kakarsulemankhel JK (2011) Prevalence of fascioliasis in cows and buffaloes in Quetta, Pakistan. *Pharmacologyonline*, *Nl* 2: 974-978.
145. Qasim S, Saleem U, Ahmad B, Aziz MT, **Qadir MI**, Mahmood S, Shahzad K (2011) Therapeutic efficacy and pharmacoeconomics evaluation of pamidronate versus zoledronic acid in multiple myeloma patients. *J App Pharm*, 04(03): 438-452.
146. Ahmad M, Anwar Z, Mahmood Q, **Qadir MI** (2011) Epilepsy: A review. *Pharmacologyonline* *Nl*, 3: 978-981.
147. Janbaz KH, **Qadir MI**, Younas F, Ali M, Malik SA (2011). Future strategies in

- treatment of parkinson's disease. *J Col Med Sci-Nepal*, 7(2): 67-71.
148. **Qadir MI**, Zafar A (2011). Emerging treatment of dementia. *J Col Med Sci-Nepal*, 7(3): 56-61.
 149. Munawar Z, **Qadir MI** (2012). Nicotine addiction: Mechanism and management. *Rev Pharmacol*, 5: 55-60.
 150. Ameen N, **Qadir MI** (2012). Hepatic viral infections, protein bio-markers and liver imaging: Risk factors & diagnostic tools for hepatocellular carcinoma. *Rev Pharmacol*, 5: 197-202.
 151. Niazi SG, Noor A, Adil A, Fatima U, **Qadir MI** (2012). Myoclonus. *Int J Drug Targets*, 3(2): 111-120.
 152. Rajoka MI, **Qadir MI**, Pervaiz N, Ibrahim Z, Bukhari SA, Ahmad B (2012) Nutrigenomics and its approaches for control of chronic diseases. *Current Biotechnology*, 1(3): 258-265.
 153. Murtaza S, **Qadir MI** (2012). Depression in breast cancer: Mechanism and management. *Rev Pharmacol*, 6: 262-268.
 154. **Qadir MI** (2012) Pronunciation of alphabets: Educate the children scientifically. *Elixir Edu Tech*, 52: 11459-11460.
 155. Janbaz KH, **Qadir MI**, Siddique M (2013). Kuru: An incurable degenerative neurological disorder. *J Pharm Cosm Sci*, 1: 13-14.
 156. Alina Z, Mahmood A, Qadeer K, Khalid A, Kousar R, Mahmood Q, **Qadir MI** (2012) Case Reports: Prescription Errors from Faisalabad, Pakistan. *Pharmacologyonline*, CR 3: 1-3.
 157. Maqbool F, Maqbool A, **Qadir MI** (2012) Re-occurrence Hepatitis C: or poor diagnostic tool? *Pharmacologyonline*, CR 3: 4-5.
 158. Yousuf A, **Qadir MI**, Bashir A (2012) Recent advances in treatment of ovarian cancer. *Pharmacologyonline*, NI 3: 1-7.
 159. Ali W, **Qadir MI**, Janbaz KH (2012) Menkes Disease: X-Chromosome linked inborn disorder of copper metabolism. *Pharmacologyonline*, NI 3: 8-11.
 160. **Qadir MI**, Arshad A, Ahmad B (2013) Zinc: Role in the management of diarrhea and cholera. *World J Clin Cases*, 1(4): 140-142.
 161. Urooj F, Gul NS, Anam A, Shahzad A, **Qadir MI** (2013) Parkinson's disease: A Review. *J Pharm Res*, 12(2): 39-42.
 162. **Qadir MI** (2013) Qadir-C34. *J Bioinnovation*. 2(5): 228-232.
 163. **Qadir MI**, Ahmed B, Ali M, Saleem M, Ali M (2013) Natural hepatoprotectives: Alternative medicines for hepatitis. *RGUHS J Pharm Sci*, 3(4): 12-20.
 164. Janbaz KH, Ashfaq MA, **Qadir MI**, Ahmad B (2014) Ovarian Cancer: Characteristics & Management. *Adv Cancer: Res & Treat*, 2014: 900592.
 165. Jalal F, Rajoka MI, **Qadir MI**, Ibrahim Z, Bukhari SA, Latif F (2014) Purification and characterization of an endoglucanase of *Scytalidium thermophilum* possessing novel catalytic and thermodynamic properties. *Current Biotechnology*, 3(2):189-196.

166. Manzoor H, **Qadir MI**, Abbas K, Ali M (2014) Vascular endothelial growth factor (VEGF) in cancer. *Afr J Pharm & Pharmacol*, 8(37): 917-923.
167. Mohsin NA, **Qadir MI** (2015) Recent structure activity relationship studies of 1,4-benzodiazepines. *Peertechz J Med Chem Res*, 1(1): 8-12.
168. Mallhi TH, Khan YH, Tanveer N, Khan AH, **Qadir MI** (2017) Commentary: Surveillance of Crimean-Congo haemorrhagic fever in Pakistan. *Frontiers in Public Health*, 5: 32.
169. Iqbal A, Asif M, **Qadir MI** (2017) Modern technologies in the management of diabetes. *JCMS Nepal*, 13(2):296-301.
170. Mallhi TH, Khan YH, Tanveer N, Khan AH, **Qadir MI** (2017) First chikungunya outbreak in Pakistan: A trail of viral attacks. *New Microbes and New Infections*. 19:13-14.
171. Noor A, **Qadir MI**, Masood A, Khan J, Ahmad S (2017) Potential of imiquimod and fulvestrant against *Mycobacterium tuberculosis* using molecular docking approach. *Peertechz J Med Chem Res*. 3(1): 023-025.
172. Naqvi STQ, Shah Z, Fatima N, **Qadir MI**, Ali A, Muhammad SA (2017) Characterization and biological studies of copper nanoparticles synthesized by *Aspergillus niger*. *J Bionanosci*, 11(2): 136-140.
173. Khan J, Masood A, Noor A, Munir A, **Qadir MI**, Ahmad S (2017) Molecular docking studies on possible neuraminidase inhibitors of influenza virus. *Annals of Antivirals and Antiretrovirals*. 1(1): 005-007.
174. Khan J, **Qadir MI** (2017) Casuarinin effects on cancer chemoprevention: Progress, potential and promise. *International Journal of Pharmacological Research*. 7(09): 175-180.
175. **Qadir MI**, Fatima K (2017) Review on pharmacological activity of Amygdalin. *Arch Can Res*, 5(4): 160.
176. Noor A, Masood A, Khan J, Abbas T, **Qadir MI** (2017) *In-silico* analysis of tenidap and its derivative as a novel 5-lipoxygenase inhibitor. *Int J Pharm Sci Dev Res*, 3(1): 036-038.
177. Khan J, Masood A, Noor A, **Qadir MI** (2017) Drug development for PCGF2 protein, involved in formation of human breast cancer by polyphenols and their derivatives extracted from *Cowania maxicana*. *Int J Pharmacy and Chemistry*, 3(6): 77-81.
178. Hussain SB, Khan J, Masood A, Noor A, Siddique K, **Qadir MI** (2017) Comparative docking study of M1 protein of influenza virus by rimantadine and its derivatives to evaluate drug efficacy. *PhOL*, 3: 105-11.
179. **Qadir MI**, Munawar A, Hussain SB (2018) Thiolutin derivatives as inhibitor of RNA-dependent RNA polymerase (RdRP) of hepatitis C virus: An *In-silico* approach. *Ann Antivir Antiretrovir*, 2(1): 1-3.
180. **Qadir MI**, Javid A (2018) Awareness about Crohn's Disease in biotechnology students. *Glo Adv Res J Med Medical Sci*, 7(3): 062-064.
181. **Qadir MI**, Akhtar Z (2018) Awareness about retinitis pigmentosa in biotechnology students. *Glo Adv Res J Med Medical Sci*, 7(3): 065-067.

182. **Qadir MI**, Ali S (2018) Oral cancer. *Glo Adv Res J Med Medical Sci*, 7(3): 068-070.
183. **Qadir MI**, Saleem A (2018) Awareness about ischemic heart disease in university biotechnology students. *Glo Adv Res J Med Medical Sci*, 7(3): 059-061.
184. **Qadir MI**, Ishfaq S (2018) Awareness about hypertension in biology students. *Int J Mod Pharma Res*, 7(2): 08-10.
185. **Qadir MI**, Mehwish (2018) Awareness about psoriasis disease. *Int J Mod Pharma Res*, 7(2): 17-18.
186. **Qadir MI**, Fatima R (2018) Awareness about heart attack in postgraduate students. *Int J Mod Pharma Res*, 7(2): 11-13.
187. **Qadir MI**, Shahzad R (2018) Awareness about obesity in postgraduate students of biotechnology. *Int J Mod Pharma Res*, 7(2): 14-16.
188. **Qadir MI**, Rizvi M (2018) Awareness about thalassemia in post graduate students. *MOJ Lymphology & Phlebology*, 2(1): 14-16.
189. **Qadir MI**, Ghalia BA (2018) Awareness survey about colorectal cancer in students of M. Phil Biotechnology at Bahauddin Zakariya University, Multan, Pakistan. *Nov Appro in Can Study*, 1(3): NACS.000514.2018.
190. **Qadir MI**, Saba G (2018) Awareness about intestinal cancer in university student. *Nov Appro in Can Study*, 1(3): NACS.000515.2018.
191. **Qadir MI**, Yasmeen A (2018) Awareness about mouth cancer in biotechnology students. *Nov Appro in Can Study*, 1(4): NACS.000516.2018.

NATIONAL

192. **Qadir MI** (2004) Historical development of gene therapy. *South Asian J Health Sci*, 4: 45-48.
193. **Qadir MI** (2008) Prevalence of human malarial parasite in Pakistan. *South Asian J Health Sci*, 8: 12-14.
194. Janbaz KH, **Qadir MI** (2011) Awareness about ways of hepatitis transmission among people of Faisalabad, Pakistan. *Acad Res Int*, 1(1): 276-279.
195. **Qadir MI** (2011) Advances in treatment of lungs cancer. *Independ Rev*, 103: 176-180.
196. Janbaz KH, **Qadir MI**, Sidiq Z (2011) Stages, alcoholism and genetic basis of breast cancer. *Acad Res Int*, 1(2): 383-385.
197. Usman M, Janbaz KH, Ali M, **Qadir MI** (2011) Surgical treatment of obesity. *Pak J Surg*, 27(3): 236-237.
198. Ali M, Ashfaq AA, **Qadir MI**, Ahmad B (2012). HIV-drug resistance: Hide, shield and strike back mechanisms in medical virology. *J Rashid Latif Med Col*, 1(1): 44-50.
199. Aslam Q, **Qadir MI**, Janbaz KH, Bokhari TH (2012). Cardiovascular disorders in AIDS patients. *J Rashid Latif Med Col*, 1(2): 18-23.
200. Ali M, Ishaq Z, **Qadir MI** (2013) Role of vitamin D and its derivatives in breast cancer management. *Pak J Clin & Biomed Res*. 1(1): 3-5.

201. Janbaz KH, Malik SA, **Qadir MI**, Tabassum N, Qayyum A, Ahmad B (2013) HR regions of env gene in HIV: PCR Diagnostic targets for AIDS. *J Rashid Latif Med Col*, 2(1): 13-15.
202. Ali M, **Qadir MI**, Saleh F (2013) DNA damage: A trigger for oncogenesis. *Pak J Clin & Biomed Res*. 1(2): 17-22.
203. **Qadir MI**, Ali M, Malik SA, Abbas K, Arshad U, Ali M, Irfan M, Hanif M, Masood MI, Saleem M, Hussain L, Gul H, Bokhari TH, Mallhi TH (2013) Effect of *Eugenia jambolana* Lam. (Myrtaceae) root extracts on blood glucose levels of experimental diabetic rabbits. *Pak J Clin & Biomed Res*. 1(2): 32-36.
204. Fayyaz S, **Qadir MI** (2013) Interplay of miRNA and HIV. *Pak J Clin & Biomed Res*. 1(2): 28-29.
205. Ali MY, **Qadir MI**, Rasool S, Abbas G, Ahmed S, Aslam Z, Haleem D, Masood S, Ahmad B (2013) Effectiveness of *Viola odorata* flower decoction for tonsillitis and peritonsillar abscess. *J Rashid Latif Med Col*, 2(2): 51-53.
206. Massud A, Usman F, Rasul A, **Qadir MI** (2014) Effect of hydroxypropyl methylcellulose, xanthan gum and carboxy methylcellulose on sustained release formulations of diclofenac sodium. *Pak J Clin & Biomed Res*. 2(1): 38-46.
207. **Qadir MI**, Naz Z (2014) Awareness about Obesity and its effects among University Students. *Pak J Clin & Biomed Res*. 2(2): 19-21.
208. **Qadir MI**, Ain HN (2014) Awareness about cancer among University students. *Pak J Clin & Biomed Res*. 2(2): 17-18.
209. **Qadir MI**, Asghar S (2014) Self medication in Bahauddin Zakariya University, Multan, Pakistan. *J Rashid Latif Med Col*, 3(2): 35-38.
210. **Qadir MI**, Hussain F, Hanif M, Wahid M (2015) Awareness about homoeopathy among University students. *Pak J Pharm Res*, 1(1): 38-40.
211. **Qadir MI**, Kanwal H (2015) Advances in the management of cerebral vascular disease. *Pak J Pharm Res*, 1(2): 86-91.
212. **Qadir MI**, Baber M, Ahmed Z (2015) *In silico* targeting of interleukin-1 by modified margaric acid. *J Rashid Latif Med Col*, 4(1): 10-12.
213. **Qadir MI**, Arshad M (2015) *In silico* study in search of mosquito repellent from *Azadirachta indica*. *J Rashid Latif Med Col*, 4(1): 21-24.
214. Mehmood M, Liaquat S, Mobeen T, **Qadir MI** (2015) Flavonoids as potent inhibitors of cholesterol esterase: *In-Silico* approach. *J Rashid Latif Med Col*, 4(2): 1-3.
215. Mobeen T, Kanwal H, Mehmood M, **Qadir MI** (2015) Novel modified ligands targeting cancer proteins: Molecular docking approach. *J Rashid Latif Med Col*, 4(2): 1-3.
216. Sajjad S, Ghaffar A, **Qadir MI** (2016) Demographic and hematologic pattern of acute myeloid leukemia patients from lower Punjab area. *Pak J Pharm Res*, 2(2): 127-135.
217. **Qadir MI**, Yasmin M (2016) Opinion about health issues regarding transgenic farm animals. *Pak J Pharm Res*, 2(2): 146-147.

218. **Qadir MI**, Malik F (2016) Pancreatic cancer: from molecular biology to management. *Pak J Pharm Res*, 2(2): 148-152.
219. Jafar A, **Qadir MI** (2016) Childhood obesity: etiology and management. *Pak J Pharm Res*, 2(2): 153-159.
220. Abbas K, Shehzad M, Asif A, **Qadir MI**, Ahmad MT (2016) Phytochemical and dermatological investigations of *Tribulus terrestris* L. *Hamdard Medicus*, 59(1): 41-51.
221. Masood A, Ahmad S, Noor A, Khan J, Haider S, **Qadir MI** (2017) Virtual screening for novel HIV-reverse transcriptase inhibitors. *Pak J Pharm Res*, 3(1): 34-38.
222. Sultana T, Bashir MF, **Qadir MI** (2017) Advancement in therapeutic efforts and tools for prevention and treatment of insulin dependent diabetes mellitis. *Pak J Pharm Res*, 3(2): 14-28.
223. Ahmad S, Masood A, Noor A, Khan J, Javed M, **Qadir MI** (2017) Flavonoid from *Carica papaya*, antiviral compounds that blocks dengue virus protein expression. *Journal of Contemporary Pharmacy*. 1(2): In Printing.

ABSTRACTS PUBLISHED (Conferences/Symposiums)

1. Mallhi TH, **Qadir MI**, Khan YH, Khan AH, Adnan AS (2014) A survey of knowledge and attitude of menopause among post-menopausal women in Pakistan. ISPOR 6th Asia-Pacific Conference Beijing, China.
2. Abbas K, Rizwani GH, **Qadir MI**, Zahid H (2015) Antimicrobial and antioxidant activity of methanolic extract of tracheal fluid of *Musa paradisiaca* L. 1st International Conference on Recent Innovations in Pharmaceutical Sciences. Riphah Institute of Pharmaceutical Sciences, Islamabad, Pakistan.
3. Abbas K, Masoud MS, Mushtaq S, **Qadir MI**, Ashfaq UA, Afzal S, Shaheer TH (2017) Isolation and susceptibility of multi-drug resistant *Styphlococcus aureus* towards medicinal plants. 4th Hamdard International Conference on Unani Medicine. Hamdard University, Karachi, Pakistan.
4. Amin QA, **Qadir MI** (2018) Hindrance of mucus in transmucosal drug delivery. International Pharmaceutics Conference. Department of Pharmaceutics, Bahauddin Zakariya University, Multan.
5. Khan J, **Qadir MI** (2018) Autophagy in natural defense mechanism and cancer. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
6. Noor A, **Qadir MI** (2018) Medicinal food preservation from microbes during packaging. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
7. Masood A, **Qadir MI** (2018) Management of infectious diseases without antibiotics. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
8. Manzoor B, **Qadir MI** (2018) Management of brain tumor. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.

9. Ahmed AN, **Qadir MI** (2018) *In-vitro* effect of Pepsi on growth of myeloma cells of mouse. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
10. Bano R, **Qadir MI** (2018) Aspergillosis: etiology, diagnosis and management. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
11. Batool F, **Qadir MI** (2018) Amyotrophic lateral sclerosis: a motor neuron degenerative disorder. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
12. Alvi GB, **Qadir MI** (2018) Zika virus: mechanism for transmission. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
13. Batool F, **Qadir MI** (2018) Genetic causes and treatment of retinoblastoma. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
14. Zafar S, **Qadir MI** (2018) Therapeutic approaches for treatment of melanoma by nanotechnology. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
15. Noor S, **Qadir MI** (2018) Use of CRISPR/CAS 9 system to inhibit HBV replication. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
16. Hussain R, **Qadir MI** (2018) Use of *Carica papaya* leaves juice to treat dengue fever. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
17. Khan HS, **Qadir MI** (2018) Understanding the small intestinal bacterial overgrowth syndrome. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
18. Tariq M, **Qadir MI** (2018) B-cell controlling NK cell to suppress anti-tumor activity. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
19. Masood I, **Qadir MI** (2018) Role of exercise for management of depression. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
20. Khan M, **Qadir MI** (2018) Listeriosis: diagnosis and treatment. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
21. Ishfaq S, **Qadir MI** (2018) Piles (hemorrhoids): causes and symptoms. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
22. Fatima R, **Qadir MI** (2018) Heart attack: symptoms, diagnosis and management. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.

23. Khan R, **Qadir MI** (2018) Breast cancer: causes, symptoms, treatment and risk reduction. Postgraduate Symposium at Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan.
24. Rehman SU, **Qadir MI** (2018) AIDS and its management. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
25. Ahmad J, **Qadir MI** (2018) Management of scabies. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
26. Idrees MM, **Qadir MI** (2018) Gastric tumor: epidemiology and risk factors. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
27. Ghafoor S, **Qadir MI** (2018) Breast cancer in pregnant women. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
28. Yasmeen A, **Qadir MI** (2018) Treatment of radiotherapy induced skin reactions by *Aloe vera*. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
29. Altaf A, **Qadir MI** (2018) Management of metastatic spinal tumor. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
30. Javaid A, **Qadir MI** (2018) Antibiotic resistance: current issue in health sciences. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
31. Akhtar Z, **Qadir MI** (2018) Stroke disease: etiology and management - an overview. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
32. Arif MH, **Qadir MI** (2018) Immunity attained by mutation in silenced B cells. *Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.*
33. Shahzad R, **Qadir MI** (2018) Acne: a major skin problem. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
34. Somroo AA, **Qadir MI** (2018) Toxic shock syndrome. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
35. Gilani M, **Qadir MI** (2018) Noise induced hearing loss: causes and effects. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
36. Awan A, **Qadir MI** (2018) Asthma: a global burden. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
37. Ali S, **Qadir MI** (2018) Brucellosis: etiology, diagnosis & management. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
38. Noureen S, **Qadir MI** (2018) Lassa fever: etiology, symptoms & treatment. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.

39. Jamshaid I, **Qadir MI** (2018) Mucormycosis: etiology, treatment. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
40. Jamil H, **Qadir MI** (2018) Management of diabetic foot ulcer. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
41. Wazir N, **Qadir MI** (2018) Brucellosis: transmission from cattle to human. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.
42. Muhammad AJ, **Qadir MI** (2018) Biogenic silver nanoparticles for breast cancer treatment. Symposium organized by Zakariyan Federation for Biotechnologists, Bahauddin Zakariya University, Multan.

BOOKS/PRACTICAL MANUALS

1. **Qadir MI** (2004) Qadir's Medical Enzymology. Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 91.
2. **Qadir MI** (2006) Forensic Pharmacy. Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 195.
3. **Qadir MI** (2006) Experimental Pharmaceutical Chemistry (Organic). Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 68.
4. **Qadir MI** (2006) Qadir's Text Book of Pharmacognosy (Part I). Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 266.
5. **Qadir MI** (2006) Qadir's Text Book of Pharmacognosy (Part II). Islamabad: Zulfiqar Ali Institute of Molecular Medicine. Pp. 356.
6. **Qadir MI** (2008) Qadir's Text Book of Clinical Biochemistry. Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 127.
7. **Qadir MI** (2009) Qadir's Text Book of Pharmaceutical Chemistry (Organic). Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 223.
8. **Qadir MI** (2009) Qadir's Text Book of Physical Pharmacy. Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 271.
9. **Qadir MI** (2009) Qadir's Text Book of Physiology. Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 282.
10. **Qadir MI** (2009) Practical Manual of Pharmaceutical Biochemistry. Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 64.
11. **Qadir MI** (2009) Manual of Experimental Pharmacognosy. Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 58.
12. **Qadir MI** (2010) Qadir's Text Book of Pharmaceutical Chemistry (Medicinal). Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 383.
13. **Qadir MI** (2010) Qadir's Text Book of Pharmacology. Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 559.
14. **Qadir MI** (2010) Qadir's Text Book of Dispensing. Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 79.

15. **Qadir MI** (2010) Qadir's Hospital Pharmacy. Islamabad, Pakistan: Zulfiqar Ali Institute of Molecular Medicine. Pp. 174.

CHAPTERS IN BOOKS

16. **Qadir MI**, Tabassam S (2017) Telomere activity and effect on cancer cells. Anticancer Therapies: Advances in Research and Applications. NOVA Science Publishers Inc., NY, USA. ISBN: 978-1-53612-611-2.
17. **Qadir MI** (2017) The Significance of synthetic peptides in liver cancer management. Anticancer Therapies: Advances in Research and Applications. NOVA Science Publishers Inc., NY, USA. ISBN: 978-1-53612-611-2.
18. **Qadir MI**, Aslam A (2017) The Importance of nanotechnology in diagnosis of liver cancer. Anticancer Therapies: Advances in Research and Applications. NOVA Science Publishers Inc., NY, USA. ISBN: 978-1-53612-611-2.
19. **Qadir MI** (2017) The role of Caspase substrates in apoptosis. Anticancer Therapies: Advances in Research and Applications. NOVA Science Publishers Inc., NY, USA. ISBN: 978-1-53612-611-2.
20. **Qadir MI** (2017) The role of an Insulin-Like Growth Factor (IGF) in carcinogenesis. Anticancer Therapies: Advances in Research and Applications. NOVA Science Publishers Inc., NY, USA. ISBN: 978-1-53612-611-2.
21. **Qadir MI** (2017) Early menarche, late menopause and advancing age: Risk factors for breast cancer. Anticancer Therapies: Advances in Research and Applications. NOVA Science Publishers Inc., NY, USA. ISBN: 978-1-53612-611-2.
22. **Qadir MI** (2017) Androgen deprivation therapy for the treatment of prostate cancer. Anticancer Therapies: Advances in Research and Applications. NOVA Science Publishers Inc., NY, USA. ISBN: 978-1-53612-611-2.
23. **Qadir MI**, Ramzan W (2017) CRISPR/cas9 System: A double edged sword in human liver cancer. Anticancer Therapies: Advances in Research and Applications. NOVA Science Publishers Inc., NY, USA. ISBN: 978-1-53612-611-2.
24. **Qadir MI**, Maqsood K (2017) The role of BRCA1 and BRCA2 gene mutation in breast cancer progression. Anticancer Therapies: Advances in Research and Applications. NOVA Science Publishers Inc., NY, USA. ISBN: 978-1-53612-611-2.
25. **Qadir MI** (2017) Cytokeratin 19: A forecasting immune-histomarker for the detection of thyroid carcinomas. Anticancer Therapies: Advances in Research and Applications. NOVA Science Publishers Inc., NY, USA. ISBN: 978-1-53612-611-2.
26. **Qadir MI** (2017) Addison's disease. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
27. **Qadir MI** (2017) Anaphylaxis. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
28. **Qadir MI**, Noor A (2017) Anemias. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
29. **Qadir MI**, Noor A (2017) Anorexia. Rare & Uncommon Diseases. Cambridge

Scholars Publishing. Newcastle, England. (In printing)

30. **Qadir MI**, Noor A (2017) Asperger's syndrome. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
31. **Qadir MI**, Noor A (2017) Autistic disorder. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
32. **Qadir MI**, Noor A (2017) Brain hemorrhage. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
33. **Qadir MI**, Masood A, Uzma R (2017) Carpal tunnel syndrome. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
34. **Qadir MI**, Masood A (2017) Crohn's disease. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
35. **Qadir MI**, Masood A (2017) Ebola. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
36. **Qadir MI**, Masood A (2017) Epilepsy. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
37. **Qadir MI**, Masood A (2017) Familial hypercholesterolemia. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
38. **Qadir MI**, Masood A (2017) Haemolytic anaemias. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
39. **Qadir MI**, Masood A (2017) Huntington disease. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
40. **Qadir MI**, Masood A (2017) Metabolic syndrome. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
41. **Qadir MI**, Khan J (2017) Migraine. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
42. **Qadir MI**, Khan J (2017) Myasthenia gravis. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
43. **Qadir MI**, Khan J (2017) Parkinson's disease. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
44. **Qadir MI**, Khan J (2017) Psoriasis. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
45. **Qadir MI**, Khan J (2017) Psychosis. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
46. **Qadir MI**, Khan J (2017) Rabies. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)

47. **Qadir MI**, Khan J (2017) Rheumatoid arthritis. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
48. **Qadir MI**, Khan J, Hashmi MN (2017) Sjogren's syndrome. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
49. **Qadir MI** (2017) Sleeping sickness. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
50. **Qadir MI** (2017) Spinal meningioma. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
51. **Qadir MI**, Ahmad S (2017) Syringomyelia. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
52. **Qadir MI**, Ahmad S (2017) Systemic lupus erythematosus. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
53. **Qadir MI**, Ahmad S (2017) Tetanus. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
54. **Qadir MI**, Ahmad S (2017) Thalassemia. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
55. **Qadir MI** (2017) Yellow fever. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)
56. **Qadir MI** (2017) Yersiniosis. Rare & Uncommon Diseases. Cambridge Scholars Publishing. Newcastle, England. (In printing)

DATA SETS PUBLISHED (GENES IDENTIFIED)

1. Muhammad SA, Ismail T, Mannan A, **Qadir MI**, Hussain SB, Shah Z, Baber M and Zafar M (2016) *Candida albicans* isolate AZM1 18S ribosomal RNA gene, partial sequence. National Center for Biotechnology Information, Gene Bank Accession No. KX557291.
2. Muhammad SA, Ismail T, **Qadir MI**, Hussain SB, Shah Z, Baber M and Zafar M (2016) *Candida albicans* isolate AZM2 18S ribosomal RNA gene, partial sequence. National Center for Biotechnology Information, Gene Bank Accession No. KX557292.
3. Muhammad SA, Fatima N, Ismail T, **Qadir MI**, Hussain SB, Shah Z, Baber M and Zafar M (2016) *Candida albicans* isolate amz3 18S ribosomal RNA gene, partial sequence. National Center for Biotechnology Information, Gene Bank Accession No. KX557293.
4. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1103 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436821.
5. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1104 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436822.

6. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1105 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436823.
7. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1106 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436824.
8. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1107 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436825.
9. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-11078 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436826.
10. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1109 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436827.
11. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1110 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436828.
12. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1111 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436829.
13. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1112 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436830.
14. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1113 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436831.
15. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1114 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436832.
16. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1115 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436833.
17. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1116 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436834.
18. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-11017 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436835.
19. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1118 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436836.

20. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1119 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436837.
21. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1120 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436838.
22. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1121 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436839.
23. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1122 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436840.
24. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1123 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436841.
25. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1124 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436842.
26. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1125 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436843
27. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1126 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436844.
28. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1127 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436845.
29. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1128 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436846.
30. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1129 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436847.
31. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1130 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436848.
32. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1131 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436849.
33. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1132 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436850.

34. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1133 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436851.
35. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1134 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436852.
36. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1135 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436853.
37. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1136 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436854.
38. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1137 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436855.
39. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1138 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436856.
40. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1139 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436857.
41. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1140 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436858.
42. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1141 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436859.
43. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1142 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436860.
44. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1143 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436861.
45. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1144 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436862.
46. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1145 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436863.
47. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1146 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436864.

48. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1147 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436865.
49. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1148 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436866.
50. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1149 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436867.
51. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1150 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436868.
52. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1151 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436869.
53. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1152 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436870.
54. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1153 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436871.
55. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1154 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436872.
56. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1155 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436873.
57. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1156 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436874.
58. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1157 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436875.
59. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1158 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436876.
60. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1159 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436877.
61. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1160 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436878.

62. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1161 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436879.
63. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1162 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436880.
64. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1163 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436881.
65. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1164 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436882.
66. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1165 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436883.
67. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1166 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436884.
68. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1167 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436885.
69. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1168 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436886.
70. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1169 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436887.
71. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1170 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436888.
72. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1171 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436889.
73. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1172 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436890.
74. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1173 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436891.
75. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1174 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436892.

76. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1175 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436893.
77. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1176 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436894.
78. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1177 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436895.
79. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1178 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436896.
80. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1179 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436897.
81. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1180 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436898.
82. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1181 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436899.
83. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1182 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436900.
84. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1183 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436901.
85. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1184 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436902.
86. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1185 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436903.
87. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1186 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436904.
88. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1187 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436905.
89. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1188 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436906.

90. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1189 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436907.
91. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1190 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436908.
92. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1191 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436909.
93. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1192 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436910.
94. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1193 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436911.
95. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1194 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436912.
96. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1195 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436913.
97. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1196 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436914.
98. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1197 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436915.
99. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1198 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436916.
100. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1199 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436917.
101. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1200 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436918.
102. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1201 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436919.
103. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1202 envelope glycoprotein (env) gene, partial cds. HR1 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436920.

104. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1103 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436921.
105. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1104 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436922.
106. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1105 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436923.
107. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1106 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436924.
108. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1107 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436925.
109. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-11078 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436926.
110. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1109 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436927.
111. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1110 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436928.
112. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1111 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436929.
113. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1112 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436930.
114. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1113 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436931.
115. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1114 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436932.
116. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1115 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436933.
117. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1116 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436934.

118. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-11017 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436935.
119. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1118 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436936.
120. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1119 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436937.
121. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1120 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436938.
122. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1121 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436939.
123. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1122 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436940.
124. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1123 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436941.
125. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1124 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436942.
126. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1125 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436943.
127. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1126 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436944.
128. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1127 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436945.
129. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1128 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436946.
130. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1129 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436947.
131. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1130 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436948.

132. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1131 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436949.
133. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1132 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436950.
134. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1133 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436951.
135. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1134 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436952.
136. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1135 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436953.
137. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1136 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436954.
138. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1137 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436955.
139. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1138 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436956.
140. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1139 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436957.
141. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1140 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436958.
142. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1141 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436959.
143. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1142 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436960.
144. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1143 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436961.
145. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1144 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436962.

146. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1145 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436963.
147. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1146 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436964.
148. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1147 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436965.
149. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1148 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436966.
150. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1149 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436967.
151. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1150 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436968.
152. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1151 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436969.
153. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1152 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436970.
154. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1153 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436971.
155. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1154 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436972.
156. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1155 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436973.
157. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1156 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436974.
158. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1157 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436975.
159. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1158 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436976.

160. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1159 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436977.
161. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1160 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436978.
162. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1161 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436979.
163. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1162 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436980.
164. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1163 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436981.
165. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1164 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436982.
166. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1165 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436983.
167. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1166 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436984.
168. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1167 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436985.
169. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1168 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436986.
170. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1169 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436987.
171. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1170 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436988.
172. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1171 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436989.
173. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1172 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436990.

174. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1173 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436991.
175. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1174 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436992.
176. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1175 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436993.
177. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1176 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436994.
178. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1177 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436995.
179. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1178 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436996.
180. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1179 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436997.
181. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1180 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436998.
182. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1181 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM436999.
183. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1182 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437000.
184. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1183 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437001.
185. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1184 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437002.
186. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1185 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437003.
187. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1186 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437004.

188. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1187 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437005.
189. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1188 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437006.
190. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1189 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437007.
191. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1190 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437008.
192. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1191 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437009.
193. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1192 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437010.
194. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1193 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437011.
195. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1194 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437012.
196. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1195 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437013.
197. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1196 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437014.
198. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1197 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437015.
199. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1198 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437016.
200. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1199 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437017.
201. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1200 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437018.

202. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1201 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437019.
203. **Qadir MI**, Malik SA (2010) Human immunodeficiency virus isolate SC-1202 envelope glycoprotein (env) gene, partial cds. HR2 region. National Center for Biotechnology Information, Gene Bank Accession No. HM437020.

NON-SCIENTIFIC/POPULAR ARTICLES

1. **Qadir MI** (1992) Sanp – Aj tak yad hi. Hamdard Nonihal, 40(7): 71.
2. **Qadir MI** (1992) Kahrora paka – Nonihal adeeb. Hamdard Nonihal, 40(8): 99.
3. **Qadir MI** (1994) Hadan wali – Ye mera Pakistan hi. Hamdard Nonihal, 42(4): 96.

THESES SUPERVISION

PhD under Supervision:

1. Waseem Raza (2014-BZBT) Genome wide meta-analysis of cDNA datasets to study genetic variants in type-II diabetes mellitus.
2. Zahra Abbas (2015-BZBT) Expression pattern, functional analysis and molecular validation of differentially expressed genes of cardiac cancer.
3. Adeel Irfan (2016-BZBT) *In-silico* evaluation and validation of hepatoprotective constituents of *Trachyspermum ammi* L.
4. Quarat-ul-Ain (2016-BZBT) *In-silico* evaluation and validation of hepatoprotective constituents of *Aconitum*.

M Phil Supervision:

5. Adnan Younus (2010-12) Activity of *Hippophae rhamnoides* berries and *Cichorium intybus* root against Methicillin-resistant *Staphylococcus aureus*.
6. Atta-ur-Rehman (2010-12) Effect of aspirin plus clopidogrel on renal function.
7. Amna Parveen (2010-12) Analgesic, antipyretic and anti-inflammatory activity of *Caesalpinia decapetala* and *Thymus linearis*.
8. Rahma Hamayun (2010-12) Analgesic, antipyretic and anti-inflammatory activity of *Malvaneglecta* and *Tamarix aphylla*.
9. Humaira Gul (2010-12) Evaluation of anti-ulcerogenic potential of *Mentha longifolia* and *Delbergia sisso* in ulcer induced rats.
10. Mohsin Ali (2010-12) To study the hepatoprotective profile in indigenous medicinal plants.
11. Sajid Ul Murad (2011-13) Hepatoprotective effects of *Lotus garcinii* and *Acacia obovata* against paracetamol induced hepatotoxicity in mice.
12. Tauqeer Hussain (2011-13) Hepatoprotective activity of *Malva parviflora* and *Morus nigra* in paracetamol induced liver injury in mice.
13. Zubair Ibrahim (2011-13) Anticancer activity of *Saccharum officinarum*, *Carthamus oxyacantha* and *Morus nigra*.

14. Attiya Nazish (2011-13) Antibacterial activity of bacteriophages against *Staphylococcus aureus*.
15. Zunaira Chauhdary (2011-13) Antibacterial activity of bacteriophages against *Escherichia coli*.
16. Muhammad Ali (2011-13) Hepatoprotective activity of *Euphorbia helioscopia* and *Viola odorata* in paracetamol induced liver injury in mice.
17. Aisha Shehzadi (2013-2015) Etiological role of Single Nucleotide Polymorphism in CYP17A1 and CYP19A1 genes in the incidence of breast cancer.
18. Amna Tariq (2013-2015) Characterization of estrogen metabolizing genes, COMT and CYP1A1, and their association with the risk of developing breast cancer.
19. Madiha Mehmood (2014-2016) Isolation and characterization of local phage of *Escherichia coli* from sewerage water.
20. Tahira Mobeen (2014-2016) Characterization of locally isolated phage strains of *Staphylococcus aureus*.
21. Sahir Sajjad (2014-2016) Molecular identification of *Micrococcus luteus* bacteriophage.
22. Amna Jafar (2015-2017) Antibacterial activity of local phage of *E. coli* isolated from sewerage water.
23. Maham Amjad (2015-2017) Antibacterial activity of locally isolated phage strains of *Staphylococcus aureus*.
24. Muhammad Farhan Bashir (2015-2017) Curcumin derivatives as CD13/Aminopeptidase-N inhibitor for evaluation of antiangiogenic agents: An *In-Silico* approach.
25. Abu Turab Haider Abdi (2015-2017) Docking study of fumagillin derivatives as inhibitor of methionine aminopeptidase-2 for evaluation of anti-angiogenesis activity.
26. Iram Irshad (2010-12) Study the hepatoprotective activity of chloroform and methanol extracts of various medicinal plants.
27. Zafar Iqbal (2010-12) Screening of analgesic activity of some indigenous medicinal plants.
28. Maria Rafiq (2010-12) Anti-bacterial and anti-fungal activity of *Portulaca olerace*, *Polygala chinensis* and *Opuntia monacantha*.
29. Saneela Ilyas (2010-12) Screening of some selected medicinal plants for their antimicrobial activity.
30. Shahnaz Akhtar (2010-12) Comparative study of hematological parameters between smokers and non-smokers taking vitamin C and vitamin E.
31. Javaria Ikram (2010-12) Study of the hepatoprotective activity of *Aryrolobium roseum* and *Malva sylvestris*.
32. Bilal Ahmad (2010-12) Evaluation of analgesic and anti-inflammatory activity of *Albizia procera* and *Aerva javanica* in animal models.
33. Fatima Javed (2011-13) Screening of *Cucumis melo* (Kharboza) and *Callestimon viminalis* (Bottle brush) for their nephroprotective activity.

34. Bilal Ahmed (2011-13) To study the hepatoprotective effect of *Nymphaea lotus*, *Chenopodium murale* and *Rumex dentatus* in mice.
35. Mahrukh (2011-13) *In vitro* antibacterial activity and acute toxicity studies of *Vicia sativa* and *Melilotus indica*.
36. Naima Idrees (2011-13) Evaluation of anti-hyperglycemic and anti-hyperlipidemic effect of *Sonchus asper* and *Prosopis juliflora*.
37. Assra Noor (2011-13) *In vivo* evaluation of *Alcea rosea* (Holyhock) and *Callistemon viminalis* (Bottle brush) for their effects on blood glucose level and lipid profile.
38. Zeshan Iqbal (2011-13) Evaluation of antibacterial activity of plant extracts of *Cestrum nocturnum* and *Cestrum diurnum* against Methicilin-resistant *Staphylococcus aureus*.
39. Ambreen Fatima, MSc (2009) Adulteration analysis of Senna (*Cassia angustifolia*) and Gum Acacia (*Acacia arabica*) available in different raw-drug shops in Faisalabad.

M Phil under Supervision:

40. Asma Noor (2016-2018) Anti-angiogenesis evaluation of betulinic acid derivatives: An *in-silico* approach.
41. Ardas Masood (2016-2018) Sinigrin as VEGF inhibitor for evaluation of anti-angiogenesis activity: A computational approach.
42. Jawaria Khan (2016-2018) Evaluation of anticoagulant activity of quercetin derivatives: A molecular docking approach.
43. Sania Ahmed (2016-2018) A virtual study to evaluate anticoagulant effect of curcumin derivatives against PLA2 enzyme.
44. Mavra Aiman (2016-2018) Isoflavones as aldose reductase inhibitor to prevent eye damage in diabetic patients: A docking study

PROJECTS, REPORTS, PC-I, ETC

1. Evaluation of stability issues of matrix tablets and pellets prepared by using aqueous polymer dispersions and organic polymer solutions. 0.50 Million by HEC
2. Characterization of estrogen metabolizing genes, and their association with the risk of developing breast cancer. 0.14 Million by BZU.
3. Characterization of strains of locally isolated bacteriophages of *E. coli*. 0.15 Million by BZU.
4. Evaluation of curcumin derivatives as antiangiogenic agents for treatment of cancer. 0.175 Million by BZU.
5. Genetic Variation in HR regions of *env* gene of HIV in Pakistan. Indigenous PhD. 1 Million by HEC.
6. Self-Assessment Report, for MSc Biotechnology at Institute of Molecular Biology & Biotechnology, Bahauddin Zakariya University, Multan, Pakistan.
7. Developed course outlines for Physical Chemistry to be taught to BS (Biotechnology) students at Institute of Molecular Biology & Biotechnology, Bahauddin Zakariya University, Multan, Pakistan.

8. Developed course outlines for Organic Chemistry to be taught to BS (Biotechnology) students at Institute of Molecular Biology & Biotechnology, Bahauddin Zakariya University, Multan, Pakistan.
9. Developed course outlines for Inorganic Chemistry to be taught to BS (Biotechnology) students at Institute of Molecular Biology & Biotechnology, Bahauddin Zakariya University, Multan, Pakistan.
10. Report submitted to Pharmacy Council of Pakistan for registration of Doctor of Pharmacy degree program at College of Pharmacy, GC University, Faisalabad (10.9.12)

REFERENCES

1. **Prof. Dr. Muhammad Baber**
Director,
Institute of Molecular Biology & Biotechnology,
Bahauddin Zakariya University, Multan, Pakistan
+92-300-6333229
2. **Prof. Dr. Muhammad Ali**
Vice-Chancellor,
GC University, Faisalabad, Pakistan
+92-333-6999131
3. **Prof. Dr. Muhammad Iqbal**
Head of Department,
Department of Pharmacy, University of Faisalabad, Faisalabad, Pakistan
+92-300-6349589
4. **Prof. Dr. Bashir Ahmad**
Dean,
Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan
+92-333-6139505
5. **Prof. Dr. Salman Akbar Malik**
Head of Department,
Department of Biochemistry, Faculty of Biological Sciences,
Quaid-i-Azam University, Islamabad, Pakistan
+92-51-90643012

SOCIAL RECOGNITION

MORE THAN 50 STORIES

**have been published in Media,
but selected are given:**

The Nation, Lahore, Saturday, November 4, 2017

Scientist invents new test to diagnose cancer

148,000 Pakistanis diagnosed with and 101,000 die of cancer every year

**MUHAMMAD IRFAZ
MULTAN**

Being a pharmacy sophomore, Imran Qadir had dreamt a decade ago of inventing a new diagnosis process of conventional cancer. Today, he has come up with 'Qadir Test'-being seen by many as a holy grail in Oncology-to detect any kind of cancer at an early stage by undergoing a simple blood test.

The test may work as a "smoke detector" by tracing changes to the plasma lipid profile that occurs when cancer is about to hit, saving thousands of lives in the coming days. Scientists believe that an early detection boosts the chances of cure and survival if the cancer is targeted before its proliferation.

"Seeing your loved ones falling prey to the killer diseases like cancer and slipping through your hands leaves scars on your mind for the whole lifetime. I felt the agony my mother and aunt faced during the diagnostic process of cancer. The ordeal pushed me to invent the test," said Dr Imran Qadir, the inventor of the Qadir Test, and assistant professor at Institute of Molecular Biology & Biotechnology at Bahauddin Zakariya University (BZU).

The approach only takes a few hours using standard laboratory equipment for the analysis of plasma lipid profile (triglycerides, cholesterol, LDL-cholesterol and HDL-cholesterol) and a

change in the profile may be used as marker for diagnosis of cancer.

Dr Qadir has laurels like the Best Young Research Scholar of the Year 2016 from Higher Education Commission and many research productivity awards from Pakistan Council for Science and Technology (PCST) to his credit.

A graduate from BZ University's Pharmacy Department, which became notoriously famous due to suspected San Bernardino shooter Tashfeen Malik, also a graduate of the same department, believes carcinogenesis, the initiation of cancer formation, may be the cause for decreased concentrations of blood lipids in cancerous patients.

"As the carcinogenesis proceeds, more cells are growing; more lipids are being used for their proliferation. Therefore, lower concentration of blood lipids, as compared to the normal person, could be utilised as marker of malignancy," he further explained.

The research to diagnose and cure the killer disease in its early stages is underway across the world. Researchers from Quest International University, Ipoh, Malaysia and Benghazi University, Libya have found relationship between serum lipids and breast cancer. Similarly, some companies like Guardant Health and Exosome Diagnostics have developed tests known as liquid biopsies that use a blood sample to replace or supplement a conventional biopsy.

Similarly, the MIT engineers have developed a pregnancy test-like diagnostic, using a urine sample to tell within minutes whether a person has cancer.

The WHO cancer statistics reveal 148,000 people are newly diagnosed with and 101,000 die of cancer in Pakistan every year. An estimate shows the number of people living beyond a cancer diagnosis reached nearly 14.5 million in 2014 and is expected to rise to almost 19 million by 2024.

"Keeping in view the horrible state, the most important concern for treatment of cancer is its timely diagnosis. But the present diagnostic tests for cancer are expensive and are either inaccessible or hard to access by the poor, leading to delayed diagnosis and ultimately death of the cancer patients," points out Dr Qadir.

The Qadir Test was developed in four stages starting from 2006 and ending in January 2016. A number of prospective studies were carried out by the researcher by taking fasting blood samples of study subjects from all the major four types of cancers: carcinomas (cancers of epithelial cells), sarcomas (cancers of connective tissues), lymphomas (cancers of lymphoid tissues), and leukemias (cancers of leukocytes and their precursors).

"None of the patients had a history of thyroid disease, diabetes or other major illness that could affect lipid metabolism. The patients were not treated with any chemotherapy,



Dr Imran Qadir

radiation or surgery either before the sample collection that may affect plasma lipid levels," he said. The studies involved about 700 patients suffering from all four kinds of cancers and the results were published by two Canadian journals European Journal of Gynaecological Oncology and Journal of Applied Pharmacy, as well as well reputed local journals like Pakistan Journal of Pharmaceutical Sciences and Pakistan Paediatric Journal.

"However, larger scale studies are yet needed to confirm the reliability of the test before it is formally prescribed by the medics," he concluded.



ہر کینسر کی وجہ وائرس، زکریا یونیورسٹی میں نئی تھیوری پیش

انسٹی ٹیوٹ آف مالیکولر بیالوجی کے ڈاکٹر عمران قادر نے تھیوری پیش کی

عالمی ادارہ ہیگل ہاؤس امریکہ نے بھی اسے تسلیم کیا، اعلیٰ سطح کی ریسرچ قرار



ملتان (خصوصی رپورٹر) زکریا یونیورسٹی کے پروفیسر نے کینسر کے بارے میں نئی تھیوری پیش

کردی جس کو قادر کینسر تھیوری کا نام دیا گیا ہے، یونیورسٹی حکام کے مطابق انسٹی ٹیوٹ آف

مالیکولر بیالوجی اینڈ بائیوٹیکنالوجی، کے اسسٹنٹ پروفیسر ڈاکٹر محمد عمران قادر نے تھیوری پیش کی، ان کی

تحقیقات نے یہ ثابت کیا کہ کینسر کی وجہ وائرس ہوتی ہے، مثال کے طور پر جگر کا کینسر ہیپاٹائٹس "بی" یا سی

وائرس، سرویکل کینسر "پاپی لوما" وائرس کی وجہ سے ہوتا ہے، ہر کینسر کی وجہ کوئی نہ کوئی وائرس ہے۔ ان کا

کہنا ہے کینسر کا علاج وائرس کی مختلف اقسام پر قابو پانے سے ممکن ہو جائے گا۔ اس تھیوری کو عالمی ادارہ

ہیگل ہاؤس امریکہ نے تسلیم کیا ہے اور وہ اس کو اپنے مجلہ میں شائع کریں گے۔ ڈائریکٹر انسٹی ٹیوٹ آف

مالیکولر بیالوجی ڈاکٹر محمد بابر نے ڈاکٹر عمران کی ریسرچ کو اعلیٰ سطح کی ریسرچ قرار دیا اور حکومت سے اپیل

کی کہ وائرس کے حوالے سے ریسرچ فنڈنگ اس ادارے کو فراہم کی جائے تاکہ کینسر کے خلاف وائرس کا

سد باب کیا جاسکے۔



ملتائے سائنسدان ڈاکٹر عمران قادر نے مقامی وائرس یافتہ کر لئے

ڈاکٹر Qadir Phages قادر فچر کا نام دیا گیا سائنسدان کا بھرپور سہولتیں فراہم کرنے پر ڈاکٹر طاہر امین اور ڈاکٹر محمد بابر کا شکریہ

ملتان (شٹاف رپورٹر) بہاء الدین زکریا یونیورسٹی ملتان ایسٹ ٹیوٹ آف مائیکولوجی بائیو ٹیکنالوجی کے سائنسدان ڈاکٹر محمد عمران قادر نے مقامی وائرس دریافت کیے ہیں جو کہ بیکٹیریا سے ہونے والی بیماریوں کے لیے مفید ثابت ہوئے ہیں۔ یہ وائرس امریکہ کے ایک مجلہ میں شائع ہوئی ہے۔ اس موقع پر ڈاکٹر عمران قادر نے ڈائریکٹر ایسٹ ٹیوٹ آف مائیکولوجی پروفیسر ڈاکٹر محمد بابر اور وائس چانسلر بہاء الدین زکریا یونیورسٹی پروفیسر ڈاکٹر طاہر امین کا شکریہ ادا کیا کہ انہوں نے ادارہ میں ایسی سہولیات مہیا کیں جس کی وجہ سے انہیں انسانی زندگی خدمت کا موقع ملا ہے۔

محقق کا نام ڈاکٹر محمد عمران قادر ہے جو 2018ء میں دیکھا جا رہا ہے کہ اپنی پانچ ٹیم اور یہ استعمال کرتے ہوئے مرض شحم فیس ہوتا۔ اصل میں بیماری پیدا کرنے والے بیکٹیریا ان اور وائرس کے خلاف مزاحمت میں کرتے ہیں اور وائرس ان کو قتل کر پاتی جس کی وجہ سے چند سالوں میں اپنی پانچ ٹیم کا استعمال بے معنی ہو جائے گا۔ اس مسئلہ کے حل کے لیے دنیا بھر کے سائنسدان کوئی نیا طریقہ دریافت کرنے کی کوششوں میں ہیں۔ اسی اثناء میں ڈاکٹر عمران قادر نے چند



زکریا یونیورسٹی کے سائنسدانوں نے

پھپھوندی میں 3 نئے جینز دریافت کر لئے

ملتان (پ ر) بہاء الدین زکریا یونیورسٹی ملتان ایسٹ ٹیوٹ آف مائیکولوجی بائیو ٹیکنالوجی کے سائنسدان ڈاکٹر سید عون محمد اور ان کے معاون پروفیسر ڈاکٹر محمد بابر، ڈاکٹر محمد عمران قادر، ڈاکٹر سید بلال حسین اور محمد ظفر نے مقامی پھپھوندی میں تین نئے جینز کی دریافت کی ہے اور ان جینز کو بین الاقوامی ادارے نیشنل سنٹر فار بائیو ٹیکنالوجی انفارمیشن کے چین بینک میں رجسٹر کروادیا ہے۔ یہ جینز اس پھپھوندی سے ہونے والی جلدی بیماریوں کے علاج کے لیے بہت اہم ثابت ہوں گے۔

TOP PHARMA SCIENTIST IN PAKISTAN



فارماسائٹس کے شعبہ میں ڈکریا یونیورسٹی کے ڈاکٹر عمران قادر کا پہلا نمبر



ملتان (خصوصی رپورٹر) بہاء الدین ڈکریا یونیورسٹی ملتان کے اسٹنٹ پروفیسر ڈاکٹر محمد عمران قادر کو پاکستان کونسل برائے سائنس و ٹیکنالوجی نے پاکستان بھر میں فارما سائنس کے شعبہ میں پہلے نمبر پر منتخب کیا ہے۔ ان کے اب تک پمفل اور انٹرنیشنل سطح کے 204 ریسرچ آرٹیکل شائع ہو چکے ہیں جبکہ پاکستان کونسل برائے سائنس و ٹیکنالوجی کی ریسرچ پروڈیکٹیوٹی 2017ء کا اعلان کر دیا۔

RESEARCH PRODUCTIVITY AWARDS



جی سی یونیورسٹی کے 17 اساتذہ میں ریسرچ پروڈیکٹیوٹی ایوارڈ تقسیم

فیکلٹی ممبران اور طلباء و طالبات کیلئے ریسرچ کے میدان میں بے پناہ مواقع موجود ہیں ڈاکٹر نورین قریشی

فیصل آباد (سٹاف رپورٹر) جی سی یونیورسٹی فیصل آباد کی ڈین آف سائنس اینڈ ٹیکنالوجی ڈاکٹر نورین قریشی نے کہا ہے کہ فیکلٹی ممبران اور طلباء و طالبات کے لئے ریسرچ کے میدان میں بے پناہ مواقع موجود ہیں جنکے ذریعے نہ صرف وہ اپنی بلکہ ملک و قوم کی ترقی میں اہم کردار ادا کر سکتے ہیں ان خیالات کا اظہار انہوں نے گزشتہ روز ڈاکٹر کیو بیٹ آف ریسرچ کے زیر اہتمام یونیورسٹی کے سات اساتذہ کو ریسرچ پروڈیکٹیوٹی ایوارڈ دینے کی تقریب سے خطاب کرتے ہوئے کیا۔ یہ ایوارڈ ڈاکٹر خالد محمود، ڈاکٹر محمد زبیر، ڈاکٹر محمد ابراہیم، عمران قادر، ڈاکٹر (باقی صفحہ 4 نمبر 6)



ڈاکٹر کیو بیٹ آف ریسرچ جی سی یونیورسٹی کے زیر اہتمام اساتذہ کو ریسرچ پروڈیکٹیوٹی ایوارڈ ڈین آف سائنس اینڈ ٹیکنالوجی ڈاکٹر نورین قریشی دے رہی ہیں

POSITION IN PHARMACY DEGREE



طالب علم کا اعزاز



بہاء الدین زکریا یونیورسٹی
کے طالب علم محمد عمران قادر
نے شعبہ فارمیسی پارٹ ون کے
پہلے سالانہ امتحان 1998ء میں
900 میں سے 594 نمبر حاصل
کر کے کلاس میں دوسری
پوزیشن حاصل کی ہے۔ عمران
قادر کا تعلق شجاع آباد سے
ہے۔

BEST YOUNG RESEARCH SCHOLAR

روزنامہ جنگ ملتان (12) 28 جون 2016ء

جامعہ زکریا کے اسسٹنٹ پروفیسر ڈاکٹر عمران
قادر کو بہترین نوجوان محقق کا ایوارڈ دیدیا گیا



ملتان (سٹاف رپورٹر) بہاء
الدین زکریا یونیورسٹی ملتان
انسٹی ٹیوٹ آف مالیکولر بیا لوجی
اینڈ بائیو ٹیکنالوجی کے
اسسٹنٹ پروفیسر ڈاکٹر محمد عمران
قادر کو ہائر ایجوکیشن کمیشن نے
ریسرچ کے میدان میں غیر معمولی خدمات کے صلہ میں
”بہترین نوجوان محقق“ کے ایوارڈ سے نوازا ہے۔ ڈاکٹر محمد
عمران قادر کی دریافت اور ایجادات میں قادر ٹیسٹ
(کینسر کا سسٹائیسٹ) اور قادر ورنائڈ (ایڈز کی دوا) قابل
ذکر ہیں۔ ڈاکٹر قادر کے 150 سے زائد مقالہ جات
مختلف قومی اور بین الاقوامی مجلہ میں شائع ہو چکے ہیں

سائیرین رانا

کئی مختلف جامعات کے طلبہ کو بھی پڑھاتے رہے۔ اس کے علاوہ ڈاکٹر عمران قادر کے 160 سے زائد مقالہ جات مختلف قومی اور بین الاقوامی مجلوں میں شائع ہو چکے ہیں۔ ان کی تحقیق، لگن اور محنت کے باعث کینسر جیسے خطرناک مرض کے ممکنہ ٹیسٹ، اب سستے ترین ہو گئے ہیں، جو یقیناً غریب عوام کے لیے کسی نعمت سے کم نہیں۔ عمومی طور پر امراض قلب کی تشخیص کے لیے ابتدائی طور پر جو ٹیسٹ کروائے جاتے ہیں ان میں کم از کم چار سے پانچ ہزار روپے خرچ ہو جاتے ہیں جب کہ ڈاکٹر عمران قادر کے تحقیق کیے گئے ٹیسٹ پر صرف مریض کے سو روپے خرچ

سائنس دیکھنا لو جی ایک ایسا شعبہ ہے جس میں طلبہ کا رجحان قدرے کم ہے، نئی چیزوں کو سیکھنے، پڑھنے کا شوق، جستجو ہر پہلو میں فطرتاً ضرور ہوتی ہے لیکن وقت، حالات اور تعلیمی سرگرمیوں کے ساتھ یہ لگن، فکر ختم ہوتی جاتی ہے، کچھ طالب علموں کے لیے کھوج کی خواہش تعلیم و تربیت کے عمل میں آنے والی رکاوٹیں پروفیشن کے چناؤ میں دشواری کا سبب بھی بنتی ہیں، تاہم ان رکاوٹوں کو عبور کر کے منزل کو حاصل کرنے کی جستجو کئے والے افراد کامیابی سے ہمکنار ہوتے اور دوسروں کے لیے بھی مشعل راہ ثابت ہوتے ہیں۔ اسکی ایک شخصیت پروفیسر ڈاکٹر عمران قادر کی بھی ہے، جنہوں نے اپنی جستجو، لگن اور جہد مسلسل سے سائنس کے شعبے میں مقام بنایا۔ وہ جامعہ بہاء الدین ذکر یا ملتان کے شعبہ انسٹی ٹیوٹ آف مائیکروبائیولوجی اینڈ بائیوٹیکنالوجی میں پروفیسر فرائض انجام دے رہے ہیں۔ حال ہی میں انہیں بہترین داخلی خدمات کے اعزاز میں ہائریجیکشن کمیشن اسلام آباد کی جانب سے ”بہترین نوجوان محقق“ کے ایوارڈ سے نوازا گیا، جس کی بنیادی وجہ کینسر کا

دوا اور ٹیسٹ کی تیاری میں حکومت پاکستان کی جانب سے بھرپور معاشی معاونت اور سہولتیں فراہم کی گئیں، اس لیے یہ ایجاد دوا و دوا اور حکومت کی ملکیت ہے۔ تعلیم و تحقیق کے لیے حکومتی سرپرستی سے متعلق کیے گئے سوال کے جواب میں ان کا کہنا تھا کہ پاکستانی قوم بہت قابل اور محنتی ہے، یہ ملک کی فلاح کے لیے کام کرنا چاہتی ہے لیکن یہاں یکساں تعلیم اور تحقیق کے لیے مواقع نہ ہونے کے برابر ہیں، جن میں آلات اور سہولتیں نہیں ہیں۔ اگر تحقیق کے لیے سازگار ماحول اور سہولتیں فراہم کردی جائیں تو ہم بھی یورپ سے کسی طور کم نہیں ہیں۔ ڈاکٹر عمران قادر کے مطابق ان کے شعبہ میں تقریباً 500 طلباء طالبات زیر تعلیم ہیں جن میں سے ان کے پاس 9 طلباء ایم فل اور تین پی ایچ ڈی کر رہے ہیں۔ طلبہ کے ساتھ تحقیق کے متعلق دل چسپ پہلو اجاگر کرتے ہوئے انہوں نے بتایا کہ ”ہم



اپنی مٹی پر اپنا علم نچھاور کرتا رہوں گا

ہمارے ملک میں تعلیم و تحقیق کے لیے مواقع نہ ہونے کے برابر ہیں کینسر کے سستے ٹیسٹ اور ایڈز کے مرض کے لیے دوا ایجاد کی

ہائریجیکشن کمیشن کی جانب سے ”نوجوان محقق“ کا ایوارڈ پانے والے، ڈاکٹر عمران قادر سے بات چیت

اس وقت "Phage"

"Therapy" پر کام کر رہے ہیں۔

ڈاکٹر کو کہتے ہیں جو اپنی بیکٹیریل اینٹیوٹی رکھتے ہیں ان کو فیکٹوری Isolate کیا ہوا ہے۔ موجودہ دور میں دیکھا جا رہا ہے کہ اینٹی بائیوٹک اڈو یہ استعمال کرنے کے باوجود مرض ختم نہیں ہو رہا اور آئندہ دس برسوں میں اپنا اترخم کر دیں گی، تو مستقبل میں کیا ہوگا۔ اس کے حل کے لیے ہم نے کچھ ایسے وائرس لے لیے ہیں جو ان بیکٹیریا کو ختم کر دیں گے، یہ تحقیق مزید دو سال تک جاری رہے گی۔ ہمارے طلبہ میں تحقیق کے حوالے سے جنون پایا جاتا ہے اور وہ کام کرنا جانتے ہیں۔ اس وقت بھی ہمارے ڈیپارٹمنٹ کے لیے جدید لیبارٹری، آلات جن میں ایکٹران مائیکروسکوپ وغیرہ شامل ہیں ہائریجیکشن کمیشن نے پراجیکٹ کو منظوری دے دی ہے۔ ان سہولتوں کے دستیاب ہونے سے ہماری کارکردگی میں بہتری آ سکے گی۔ یہ پراجیکٹ 2018ء میں مکمل ہو جائے گا۔“ ڈاکٹر عمران قادر نے نوجوانوں کو پیغام دیتے ہوئے کہا کہ وہ اپنی تمام تر توانائیاں تعلیمی عمل پر صرف کریں اور اپنی صلاحیتوں سے ملک و قوم کو مستند کریں کیوں کہ اس ملک کو قابل نوجوانوں کی ضرورت ہے اور یہ ہم پر اس ملک کا فرض بھی ہے کہ جس نے ہمیں مٹی سے سونا بنایا، ہم اس کی فلاح کے لیے کام کریں۔ ان کا کہنا ہے کہ میری تمام کام باپاں، بیویاں، میرے والدین، اساتذہ، بیوی بچوں کے دم سے ہیں اور میں اپنی مٹی پر اپنا علم نچھاور کرتا رہوں گا۔

کی نشان دہی کی جاسکتی ہے۔ یہ ٹیسٹ ہر لیبارٹری سے ایک سو روپے میں کروایا جاسکتا ہے۔ ایڈز کی دوا ایجاد کرنے سے متعلق ڈاکٹر قادر نے ہمیں بتایا کہ انہوں نے "Vertide Qadir" کے نام سے ایک دوا ایجاد کی جو پاکستان میں موجود ایڈز کے مریضوں پر تحقیق کر کے بنائی گئی ہے کیوں کہ ایڈز کے مریضوں کو جو دوا "Enfuvirtide" دی جاتی ہے وہ پاکستانی مریضوں پر اثر نہیں کر رہی تھی کیوں کہ یورپ میں بنائی گئی دوا وہیں کے مریضوں کے جینز سے مطابقت رکھتی ہے جب کہ پاکستانی مریضوں کے جینز یورپ کے مریضوں سے مختلف ہیں۔ ”میری ایجاد کردہ دوا کو ابھی باقاعدہ طور پر کلینکل ٹیسٹ سے نہیں گزارا گیا اور نہ ہی باقاعدہ کسی مریض پر اپلائی کی گیا ہے کیوں کہ اس کے لیے دوا اور مریض دونوں کے کلینکل ٹرائل رجسٹرڈ کروائے جاتے ہیں۔ دوا کے حصول کے لیے مختلف نجی کمپنیاں مجھ سے رابطے میں ہیں مگر میری خواہش ہے کہ حکومتی سرپرستی میں عوام کے لیے سستے علاج اور ٹیسٹ کرائے جائیں، کمپنیاں اگر خود کام کریں گی تو پھر دوا اور ٹیسٹ ممکنہ ہو جائیں گے۔“ ایڈز کی دوا کے متعلق ڈاکٹر قادر نے مزید بتایا کہ ایم فل کے دوران قائد اعظم یونیورسٹی اور پھر اسپتال کے ساتھ مل کر یہ تحقیق کی۔ 2011ء میں اس کا باقاعدہ اعلان کیا گیا تھا۔ اس




ہوں گے۔ ان کے مطابق عام طور پر کینسر کے مریض کالینڈر پروفائل Lipid Profile لئے کوکلیسٹرول کا لیول چیک کرنے والا ٹیسٹ بھی کیا جاسکتا ہے، یہ ٹیسٹ امراض قلب میں جتنا مریضوں کا ہوتا ہے مگر اس کو کینسر کے مریضوں پر بھی اپلائی کیا گیا، جس میں HDL، LDL، کوکلیسٹرول اور ٹوٹل لیپڈ کو چیک کیا جاتا ہے، اگر ان کے لیول مریض میں نارمل لیول سے کم ہو رہے ہوں تو مرض موجود ہونے

سستا ٹیسٹ اور ایڈز کے مرض کے لیے دوا کی ایجاد ہے۔ ملتان کے نواحی علاقے شیخ آباد سے تعلق رکھنے والے ڈاکٹر عمران قادر نے تمام تعلیمی مدارج میں امتیازی پوزیشن حاصل کی، جامعہ ذکر یا ملتان سے پی ایچ ڈی مکمل کرنے کے بعد قائد اعظم یونیورسٹی اسلام آباد سے ایم فل اور پی ایچ ڈی کی ڈگریاں حاصل کیں، تعلیم کے ساتھ ساتھ انہوں نے ملازمت اور تحقیقی سڑک بھی جاری رکھا، جب کہ تعلیمی تجربات کے ساتھ ملک

شائین رانا

کینسر کے مریض کالپڈ پروفائل Lipid Profile جس کو کولیسٹرول بھی کہہ سکتے ہیں کالپڈ چیک کیا جاتا ہے۔ یہ ٹیسٹ دل کے مریضوں کا ہوتا ہے مگر اس کو کینسر کے مریض پر بھی اپلائی کیا گیا جس میں HDL، LDL، کولیسٹرول اور ٹری گلیسیرائیڈ کو چیک کیا جاتا ہے۔ اگر ان کے لیول مریض میں نارمل لیول سے کم ہو رہے ہوں تو مرض موجود ہونے کی نشاندہی کی جاسکتی ہے۔ یہ ٹیسٹ ہر لیبارٹری سے ایک سو روپے میں کرایا جاسکتا ہے۔ اسی طرح ڈاکٹر عمران قادر نے ایڈز کی دوا ایجاد کرنے کے متعلق بتایا کہ انہوں نے "Vertide Qadir" کے نام سے ایڈز کی دوا ایڈز کے پاکستانی مریضوں پر تحقیق کر کے بنائی ہے کیونکہ ایڈز کے مریضوں پر جو دوا

سائنس و ٹیکنالوجی ایک ایسی فیلڈ ہے جس میں طلبہ کا رجحان قدر سے کم ہے کھوج کی خواہش بچوں میں بچپن میں ہی ہوتی ہے مگر ان کی تعلیم و تربیت کے عمل میں آنے والی رکاوٹیں پروفیشن کے چناؤ میں دشواری کا سبب بنتی ہیں۔ تاہم ان رکاوٹوں کو عبور کر کے منزل کو حاصل کرنے کی جستجو رکھنے والے افراد کامیابی سے ہمکنار ہوتے ہیں جو یقیناً دوسروں کیلئے بھی شعل راہ ثابت ہوتے ہیں کہ ان کی سائنس کے میدان میں خدمات معاشرے کی بھلائی و بہتری کا باعث بنتی ہے۔ ایسی ہی خدمات کا سہرا پروفیسر ڈاکٹر عمران قادر کے سر پر سجا ہے۔ جامعہ بہاء



”اپنی مٹی پر اپنا علم نچھاور کر تار ہوں گا“

ریسرچ میں غیر معمولی خدمات پر بہترین نوجوان محقق کا ایوارڈ لینے والے ڈاکٹر عمران قادر سے بات چیت

کینسر کا سسٹائیسٹ اور ایڈز کے مریضوں کیلئے دوا ایجاد کرنے پر ہائر ایجوکیشن کمیشن نے ایوارڈ سے نوازا

اسسٹنٹ پروفیسر عمران قادر جامعہ ذریعہ کے انسٹی ٹیوٹ آف مالیکیولر بائیولوجی اینڈ بائیوٹیکنالوجی میں فرائض انجام دے رہے ہیں

ہو رہا اور آئندہ دس سالوں میں اپنا ختم کر دیں گی تو کیا مستقبل ہوگا۔ اس کے حل کیلئے ہم نے کچھ ایسے وائرس لے لیے ہیں جو ان بیکٹیریا کو ختم کریں گے۔ اس تحقیق پر مزید دو سال لگ جائیں گے۔ ہمارے طلبہ میں تحقیق کے حوالے سے جنون پایا جاتا ہے اور وہ کام کرنا جانتے ہیں۔ مجھے بھی ہمیشہ حکومتی اداروں کا تعاون رہا ہے۔ اس وقت بھی ہمارے ڈیپارٹمنٹ کیلئے جدید لیبارٹری، آلات جن میں الیکٹران مائیکروسکوپ وغیرہ شامل ہیں ہائر ایجوکیشن کمیشن نے پراجیکٹ کو Approve کر لیا ہے۔ ان سہولیات کے دستیاب ہونے سے بہتر فراہم کر سکیں گے۔ یہ پراجیکٹ 2018ء میں مکمل ہو جائے گا۔ ڈاکٹر عمران قادر نے جہاں میڈیٹ کیلئے کیلئے گراں قدر خدمات انجام دی ہیں وہیں بحیثیت ماہر تعلیم بھی انہوں نے ایک ریسرچ ڈسٹریکٹ کھلا جس میں انہوں نے ڈکٹری و لغت بنانے کی تجویز پیش کی ہے اور اس کا نام "Qadir Pronunciation" رکھا ہے۔ ڈاکٹر عمران کے مطابق بچے کو حروف تہجی کیلئے جوڑ کر انے جاتے ہیں لیکن اگر بچوں کو صرف ان حروف کی آواز سے پہچان کرانی جائے تو وہ کم وقت میں بہتر انداز سے پڑھ اور لکھ سکیں گے۔ اس کیلئے وفاقی ادارہ برائے اردو سے اپروڈ کر کر اساتذہ کو ورکشاپ کرائی جائے جس کے دور رس نتائج برآمد ہوں گے۔ ڈاکٹر عمران قادر نے نوجوانوں کو اپنے پیغام میں کہا کہ وہ اپنی توانائیاں تعلیمی عمل کو یکھنے پر صرف کریں اور اپنی صلاحیتوں سے ملک کو قوم کو مستفید کریں کیونکہ یہ ہم پر اس ملک کا فرض ہے کہ جس نے ہمیں مٹی سے سونا بنایا دیا ہے۔ انہوں نے اپنی ترقی کا ریڈٹ حکومتی اداروں، والدین، اساتذہ اور اپنے ہی بچوں کو دیا ہے کہ ان سب کے تعاون کے باعث ہی وہ تعلیم و تحقیق کا عمل جاری رکھے ہوئے ہیں اور اپنی مٹی کو اپنا علم نچھاور کرتے رہیں گے۔



گئے سوال کے جواب میں کہا کہ پاکستانی قوم ایسی مٹی سے بنی ہے کہ ان کے پاس دماغ ہے اور یہ کام کرنا چاہتی ہے لیکن تعلیم کے ساتھ اگر تحقیق کی بات کی جائے تو سہولیات نہ ہونے کے برابر ہیں جن میں آلات اور ٹیکنیکل نہیں ہیں۔ اگر تحقیق کیلئے سازگار ماحول اور سہولیات فراہم کر دی جائیں تو ہم بھی یورپ سے قطعاً کم قوم نہیں ہیں۔ اسی طرح اگر جنوبی پنجاب میں موجود سہولیات کا موازنہ ملک کے بڑے شہروں سے کیا جائے تو کافی کم دکھائی دیتی ہیں مگر بحیثیت اساتذہ کوشش کرتے ہیں کہ محدود وسائل میں رہتے ہوئے معیاری تحقیق ممکن بنائی جاسکے۔ اس کیلئے طلبہ کو بڑے شہروں کی جامعات اور تحقیقی اداروں میں بھیج دیا جاتا ہے۔ ڈاکٹر عمران قادر کے مطابق ان کے شعبہ میں تقریباً 500 طلبا و طالبات زیر تعلیم ہیں جن میں سے ان کے پاس 9 طلبا بہم نقل اور تین بی ایچ ڈی کے ہیں۔ اپنے طلبہ کے ساتھ تحقیق کے متعلق دلچسپ پہلو اچا کر کرتے ہوئے بتایا کہ اس وقت ہم "Phage Therapy" پر کام کر رہے ہیں۔ "Phage" وائرس کو کہتے ہیں جو انٹی بیکٹیریل ایکٹیوٹی رکھتے ہیں ان کو پکڑ کر Isolate کیا ہوا ہے۔ موجودہ دور میں دیکھا جا رہا ہے کہ انٹی بایوٹک ادویہ استعمال کرنے کے باوجود مرض ختم نہیں

"Enfuvirtide" پاکستانی مریضوں پر انٹریس کر رہی تھی کیونکہ یورپ میں بنائی گئی دوا وہیں کے مریضوں کے جینز سے مطابقت رکھتی ہے جبکہ پاکستانی مریضوں کے جینز یورپ کے مریضوں سے مختلف ہیں اسی لئے دوا انٹریس نہیں ہے جبکہ ڈاکٹر قادر کی تیار کردہ دوا یہاں کے مریضوں پر انٹریس کی۔ ڈاکٹر عمران قادر کی دوا کو ابھی باقاعدہ طور پر کلینکل ٹیسٹ سے نہیں گزارا گیا اور نہ باقاعدہ مٹی مریض پر اپلائی کی گئی ہے کیونکہ اس کیلئے دوا اور مریض دونوں کے کلینکل ٹرائل رجسٹر کرائے جاتے ہیں۔ دوا کے حصول کیلئے کمپنیاں رابطے میں ہیں مگر ان کی خواہش ہے کہ حکومتی سرپرستی میں دونوں ریفرنوں کو لے کر عام عوام کیلئے سے علاج اور ٹیسٹ کو رکھا جائے کیونکہ کمپنیاں اگر خود کام کریں گی تو پھر دوا اور ٹیسٹ جھگڑے ہو جائیں گے۔ ایڈز کی دوا کے متعلق مزید بتایا کہ ایم فل کے دوران قائد اعظم یونیورسٹی اور پھر ہسپتال کے ساتھ مل کر یہ ریسرچ کی اور 2011ء میں اس کا باقاعدہ اعلان کیا گیا تھا۔ اس دوا اور ٹیسٹ کی تیاری میں حکومت پاکستان کی جانب سے بھرپور معاشی معاونت اور سہولیات مہیا کی گئیں۔ اس لئے یہ ایجاد عوام اور حکومت کی ملکیت ہے۔ تعلیم و تحقیق کیلئے حکومتی سرپرستی کے متعلق کئے

المدین ذریعہ پاکستان کے شعبہ انسٹی ٹیوٹ آف مالیکیولر بائیولوجی اینڈ بائیوٹیکنالوجی میں بطور اسسٹنٹ پروفیسر فرائض انجام دینے والے پروفیسر ڈاکٹر عمران قادر کو حال میں ہی ان کی بہترین و اعلیٰ خدمات کے اعزاز میں ہائر ایجوکیشن کمیشن اسلام آباد کی جانب سے ”بہترین نوجوان محقق“ کے ایوارڈ سے نوازا گیا ہے جن کے پیچھے موصوف کی برسوں کی محنت شامل ہے۔ ملتان کے نواحی علاقے شجاع آباد سے تعلق رکھنے والے ڈاکٹر عمران قادر نے تمام تعلیمی مدارج میں امتیازی پوزیشن برقرار رکھی ہیں وجہ ہے کہ جامعہ ذریعہ ملتان سے بی فارمیسی مکمل کرنے کے بعد قائد اعظم یونیورسٹی اسلام آباد سے ایم فل اور پی ایچ ڈی کی اعلیٰ ڈگریاں حاصل کیں جبکہ ساتھ ہی عملی زندگی یعنی ملازمت کرتے رہے اور اپنے تحقیقاتی سفر کو بھی جاری رکھا۔ تعلیمی و تحقیقی تجربے کے ساتھ ملک کی مختلف جامعات کے طلبہ کو بھی پڑھا رہے۔ پروفیسر ڈاکٹر عمران قادر کو ہائر ایجوکیشن کمیشن کی جانب سے نوجوان محقق کا ایوارڈ ان کی دریافت اور ایجاد کے باعث ملا جو قائد اعظم یونیورسٹی کینسر کا سسٹائیسٹ اور قادر ورنائڈ یعنی ایڈز کی دوا کی ایجاد قابل ذکر ہے۔ اس کے علاوہ موصوف کے 160 سے زائد مقالہ جات مختلف قومی اور بین الاقوامی مجلوں میں شائع ہو چکے ہیں اور یہ ایوارڈ چالیس سال سے کم عمر افراد کو دیا جاتا ہے۔ ڈاکٹر عمران قادر نے تدریس کے ساتھ تحقیق پر بھی خصوصی توجہ مرکوز رکھی جس کے باعث اس قدر اہم اور ہنگامی تحقیق پر عوام کی رسائی کو ممکن بنا سکے ہیں۔ ڈاکٹر عمران قادر نے کینسر کا سسٹائیسٹ ٹیسٹ بنایا ہے عمومی طور پر دل کیلئے ابتدائی طور پر ٹیسٹ کرائے جاتے ہیں مریض کے کم سے کم بھی چار سے پانچ ہزار روپے خرچ ہو جاتے ہیں جبکہ ڈاکٹر عمران قادر کے تحقیق کئے گئے ٹیسٹ پر صرف مریض کے ایک سو روپے خرچ ہوں گے۔ ڈاکٹر عمران قادر کے مطابق عام طور پر